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Recombinant antibodies have increased in prominence as therapeutics and 
diagnostic tools since their introduction to the market in the mid-1980’s.  They are used 
to treat diverse conditions from Crohn’s disease to cancer.  Since the Anthrax letter 
attacks of 2001, a great deal of work has been carried out to develop therapeutics to this 
disease, and antibodies that neutralize the toxic action of Bacillus anthracis are 
prominent among them. 
This dissertation describes the elucidation of the structure of the 14B7 family of 
neutralizing antibodies directed at protective antigen (PA) of B. anthracis and the 
complex of PA domain 4 (PAD4) with an ultra-high affinity neutralizing antibody (M18), 
and then utilizes this information to aid in the engineering of the antibody to various 
ends.  Chapter 2 presents the structure of the M18-PAD4 complex and of the 14B7 family 
of antibodies, which aids in the understanding of the affinity maturation process for this 
antibody family.  Chapter 3 describes the affinity maturation of M18 to a PA variant by 
applying the knowledge gained from the complex structure.  This previously intractable 
challenge was met by employing saturation mutagenesis in highly focused libraries to 
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M18 directed by the complex structure to the area of variation on PA.  These results 
indicate that this could be a generalizable method for the engineering of M18 to natural 
and deliberate variation of PA.  Chapter 4 reports work toward the development of a 
reversible, photoresponsive antibody using small molecule and polymer-protein 
conjugates.  The results indicate that a probable site on M18 was located for placement of 
the polymer appendage, although further work is necessary to empirically refine the 
properties of the photoresponsive polymer. Chapter 5 presents an unrelated project, 
which was to confirm the existence of a proposed RNA thermosensor in the 5’ 
untranslated region of LcrF from the pathogenic bacterium Yersinia pestis, the causative 
agent of plague. 
Overall, these studies reveal the power of structure-based engineering in this 
antibody-antigen system.  In addition, the structural elucidation of the M18-PAD4 
complex and the 14B7 family of antibodies furthers our basic understanding of protein-
protein interactions and the process of affinity maturation of antibodies. 
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CHAPTER 1 
Introduction and Background 
 
1.1 ANTIBODY THERAPEUTICS 
Antibodies have become an integral sector of the human therapeutics and 
diagnostics market.  With therapies designed to treat maladies from Crohn’s Disease to 
cancer, antibodies have become a mainstay in the physician’s arsenal over the past twenty 
years.  From the first United States Food and Drug Administration (FDA) approval in 
1986, the use of antibodies has increased to become a multi-billion dollar industry.  
Currently, there are 26 antibodies licensed by the US FDA for use as therapeutics or 
imaging agents, and their application generated $31 billion in worldwide revenue for 
2007 (Johnson 2008).  In 2004, forecasters predicted that the 2008 therapeutic antibody 
market would generate $16.7 billion in revenue (Pavlou and Belsey 2005); however, the 
market outpaced these predictions and had already achieved $19 billion in revenue during 
2006.  With a current estimated annual growth rate of 16%, analysts forecast $56 billion 
in projected revenue for antibody therapeutics in 2012 (Johnson 2008).  With the 
approval of antibodies by the FDA maintaining a constant trajectory over almost fifteen 
years, and with the existence of a healthy pipeline of antibody therapeutics under 
investigation currently, it appears that these forecasts should be met or exceeded as were 
previous predictions.  Because the use of antibodies is a high-growth area in the 
therapeutic market, considerable research is being carried out with regard to targets, 
selection systems, expression systems, and scale-up.  
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Antibodies represent one of the main lines of natural defense against disease and 
infection.  Antibodies recognize intruders as non-self and trigger an immune response.  
Evolutionary ancestors to antibodies exist even in sharks.   
In our immune system, we have several different versions of immunoglobulins 
(Ig): IgA, IgD, IgG, IgE, and IgM.  IgA is the major antibody utilized in mucosal 
immunity, which exists primarily in the dimeric state.  IgD is a monomeric antibody that 
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is displayed on the surface of B cells.  IgG is the primary form of secreted antibody in the 
immune system.  It is monomeric, and is able to cross the placenta to provide immunity 
to a gestating fetus before it has developed an immune system of its own.  IgE is another 
monomeric form of antibody that is implicated in allergy and the fighting of gut parasites 
and protozoans.  Finally, IgM is the largest antibody, at 900 kD.  It exists primarily as a 
pentamer, and is the first antibody expressed by mature B cells.  Because of its 10 
binding sites, with two per monomer, it has very high avidity that makes up for generally 
lower binding site affinities.   
These antibodies are all expressed from B cells, which use recombination of a set 
of V, D, and J genes to create diversity that can recognize antigens of foreign organisms 
(Market and Papavasiliou 2003).  Early in the development of B cells, each individual 
cell recombines these genes to create unique variable regions for the heavy and light 
chains of the immunoglobulin that it is to express.  If this B cell recognizes its antigen 
specifically and becomes co-stimulated by helper T cells, it will migrate to the peripheral 
lymph glands and become a centroblast B cell, and begin the process of creating a high 
affinity, soluble IgG (Li et al. 2004).   
At this point, two processes occur that lead to soluble expression of high affinity 
IgG: somatic hypermutation and antibody class switching.  As stimulated B cells divide, 
they increase the mutation rate in the variable regions of their immunoglobulins which 
leads to affinity maturation of the immunoglobulin and the production of better binders 
(Li et al. 2004) in a stochastic process.  Class switching is a recombination process in 
which the constant regions of the antibody are switched, allowing any of the different 
forms of immunoglobulins previously mentioned to be expressed (Stavnezer and 
Amemiya 2004).  As most of the antibodies presented in the body are in the IgG form, 




The basic form of an antibody is represented as the familiar “Y” format, 
consisting of two heavy chains and two light chains which pair as a “dimer of 
heterodimers.”  That is, one light chain pairs with a heavy chain to make a binding unit, 
and two of these heterodimers pair to form the full immunoglobulin.  Both heavy and 
light chains have constant and variable regions; light chains are composed of a variable 
(VL) and constant region (CL), and heavy chains are composed of a variable (VH) and 
three constant regions (CH1, CH2, and CH3).  Variable and light chains are held together by 
a disulfide bond formed between CL and CH1 regions, and the constant regions of each 
side of the “Y” are held together by disulfide bonds formed between interstitial “hinge” 
regions intervening between CH1 and CH2 domains.  VH and VL interact to form the 
minimal binding unit of an antibody, interfacing to create the binding surface that 
contacts antigen; this is also known as the variable fragment or Fv.  Various forms of 
truncation and addition of linker regions can be utilized to aid in cloning, expression, and 
stability of these antibody fragments.  The most common antibody fragments utilized are 
Fab, scFv, and scAb fragments.  A Fab fragment is composed of the full light chain (VL 
and CL) interacting with the VH and CH1 regions of the heavy chain.  scFv fragments are 
composed only of the VL and VH regions, connected with a flexible linker in between; 
this single gene can be constructed in either VL-linker-VH or VH-linker-VL orientations.  
A common flexible linker sequence is twenty amino acids composed of four repeats of 
GGGGS (four glycines followed by a single serine).  The scFv is often used because it 
represents the minimal binding unit of an antibody that is expressed in a single 
polypeptide chain.  The final antibody fragment defined here is the scAb, which is an 
scFv with a CL domain fused to the C-terminus.  This format is used at times to increase 
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expression of an antibody fragment, as fusion to the CL domain has been implicated in 
increased soluble expression (Hayhurst 2000); additionally, this format can be useful 
when screening by ELISA, as it adds another domain that can be easily targeted for 




































































The binding unit of an antibody that recognizes an antigen is contained within the 
variable regions; the surface of interaction is generally composed of the complementarity 
determining regions (CDRs) with framework regions (FRs) located in between.  There 
are 3 CDRs and 4 FRs in each variable chain (heavy and light), yielding a total of 6 
CDRs that contain the binding site; generally, all six CDRs make contact with their 
protein antigen (Sheriff et al. 1987; Padlan et al. 1989; Huang et al. 1998; Mylvaganam 
et al. 1998; Prasad et al. 1998; Li et al. 2000; Niemi et al. 2007), and they typically target 
a discontinuous epitope (Padlan et al. 1989; Fischmann et al. 1991; Tulip et al. 1992; Su 
et al. 2007).  For protein antigens, the surface of interaction is primarily flat and 
rectangular (Amit et al. 1986; Sheriff et al. 1987), though exceptions have been observed 
(Bossart-Whitaker et al. 1995); hapten binders typically have a trough into which the 
small molecule is accommodated.  Solvation of the complex interface can be sparse to 
extensive (Braden et al. 1994; Cohen et al. 1996), and solvent molecules, typically water, 
can intercede to create stable hydrogen bond bridges that may aid in the binding 
interaction (Braden et al. 1995; Li et al. 2000).   
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Figure 1.3.  scFv structure.  VH is light blue, VL is dark blue, CDR’s are green, disulfide 
bonds are orange. 
X-ray crystallographic structures of a series of affinity matured anti-lysozyme 
antibodies in complex with their antigen revealed that the two main driving forces for 
antibody affinity were shape complementarity and the ability to bury apolar surfaces.  
Energetics of the interaction appeared to be dominated by a core hydrophobic interaction 
that was encircled by other interactions (Li et al. 2003).  These studies revealed that 
affinity maturation appeared to occur when more hydrophobic interactions were created 
peripheral to this core interaction by rearrangements of amino acid residues.  Apart from 
the portions of antibody responsible for creating and supporting the antigen binding site, 
the CH2 and CH3 regions are the domains of the antibody that are responsible for 
interacting with the immune system to initiate effector functions, such as complement 
activation or phagocytosis. 
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1.3 ANTIBODY ENGINEERING 
The term antibody engineering refers to the laboratory process by which an 
antibody is given beneficial characteristics.  This process can utilize rational design or 
directed evolution, and is often used when referring to affinity maturation, or the 
engineering of antibodies to bind with higher affinity to their cognate antigen.  However, 
antibody engineering also describes proesses such as engineering hyperstable frameworks 
(Proba et al. 1998), antibodies that can function in a reducing environment, called 
intrabodies (Messer and McLear 2006; Williams and Zhu 2006; Cardinale and Biocca 
2008; Lo et al. 2008), or the altering of constant regions to perform specific effector 
functions.  Recent advances have been made in the use of computational approaches to 
aid in the design of antigen binding sites (Barderas et al. 2008).  However, a great deal of 
antibody engineering involves the directed evolution of antibody fragments by 
introducing diversity to the antibody gene and then screening that library for enhanced 
characteristics.  To that end, there are a number of protein display systems that have been 
developed for this purpose.  These differ by the organisms that they utilize, but the 
common, and most important, feature of each is that they allow the linking of the 
genotype (DNA encoding the antibody fragment gene) to the phenotype (protein form of 
the antibody fragment). 
 
1.3.1 Phage Display 
The most commonly utilized display system for engineering of proteins has been 
phage display.  Roughly 300 publications a year are produced featuring this technique 
(Gai and Wittrup 2007).  With antibody engineering, the most common usage is to 
display the scFv antibody fragment on the surface of a filamentous phage, like fd or M13, 
through fusion with one of the viral coat proteins (Gao et al. 1999).  A fusion protein 
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with gene III is the most widespread (Barbas et al. 1991), as it has fewer limitations as 
compared to other coat proteins, though other protein fusions have been used (Gao et al. 
2002).  When the phage library is constructed, the phage particles exhibit scFv proteins 
decorated on the exterior, while the DNA encoding the scFv gene is located inside.   
 
Figure 1.4.  Schematic representation of the structure of the filamentous phage fd (Gao et 
al. 1999). 
 
The phage library is exposed to antigen that is tethered either to beads or a solid 
surface, allowed to bind, washed to remove nonspecific binding phage, eluted, and then 
the library is used to infect bacteria in order to repropagate the selected phage.  This 
process is called panning, and successive rounds of increasing stringency can be utilized 
to select for tighter binding clones.  Because the phage particle contains approximately 5 
copies of gene III, scFv fusions can be displayed multiple times which leads to avidity 
effects rather than solely affinity as the primary selection parameter.  The panning 
procedures have been improved upon to help eliminate avidity issues during selection 
(Hoogenboom 2002).  Regardless of its potential limitations, phage display has resulted 
in the isolation of numerous antibodies in the twenty years since its introduction. 
 
 10 
1.3.2 Yeast Surface Display 
Another competing technology that has been adopted as a mainstream display 
system is yeast display.  In this technique, a library of protein variants is expressed as a 
fusion protein with a membrane protein of the yeast cell.  A common format for this is a 
C-terminal fusion with the yeast agglutinin protein Aga2p (Wittrup 2001; Gai and 
Wittrup 2007).  Because yeast is a single celled eukaryote, it can apply post-translational 
modifications and quality control for folding of proteins in the golgi and endoplasmic 
reticulum; this allows for mostly correctly folded protein to be displayed for selection 
purposes (Shusta et al. 1998; Boder et al. 2000).  When a yeast-displayed library of 
antibody fragment variants is incubated with fluorescently-labeled antigen, the library 
can then be screened using high-throughput methods like Fluorescence Activated Cell 
Sorting (FACS) to obtain an enriched population that can be regrown, relabeled, and 
resorted until sufficient enrichment is observed.  This technique has been increasing in 
popularity since its introduction slightly over ten years ago, and the number of 
publications utilizing yeast display is currently experiencing exponential growth (Gai and 
Wittrup 2007). 
 
1.3.3 Gram Positive Surface Display 
With only a single membrane, one might think that gram positive bacteria would 
be an ideal candidate for display systems.  Surface display of proteins on gram positive 
bacteria for the purpose of directed evolution has been largely overlooked however, 
primarily due to the low transformation efficiency of most gram positive strains.  
However, recent studies have shown that affinity proteins, “affibodies,” that are derived 
from a staphylococcal protein A domain with a variant binding region can be selected to 
bind to Tumor Necrosis Factor alpha (TNFα) from a large library of greater than 106 
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clones while displayed on the surface of Staphylococcus carnosus.  Proteins with 
apparent affinities of 95 pM to 2.2 nM were selected (Kronqvist et al. 2008).  While this 
is not selection based upon a traditional antibody framework, scFvs have been expressed 
successfully on the surface of gram positive bacteria previously (Gunneriusson et al. 
1996), so presumably scFv screening can be carried out in a similar fashion. 
 
1.3.4 Gram Negative Display Systems 
Because of its use as the workhorse of molecular biology, the gram negative 
bacterium Escherichia coli is an excellent platform for use as a display system for 
directed evolution experiments.  With numerous facile cloning systems, highly efficient 
transformation efficiencies, and an oxidizing periplasmic space to aid in the proper 
folding of proteins containing disulfide bonds, this widely used bacterium is an ideal 
candidate for protein display, and great effort has been spent to develop it as a successful 
approach. 
 
1.3.4.1 Lpp-OmpA Surface Display 
One of the first bacterial display technologies that would go on to provide a 
successful platform for antibody fragment directed evolution was the Lpp-OmpA display 
system.  Our laboratory created a fusion system that could display an active, soluble 
protein, β-lactamase, on the outside of the outer membrane of E. coli (Francisco et al. 
1992).  It utilized a construct that carried the signal sequence and first nine amino acids 
of Braun’s lipoprotein (Lpp), residues 46-159 of outer membrane protein A (OmpA), 
followed by the β-lactamase protein.  The Lpp domain was responsible for anchoring the 
fusion protein to the inside of the outer membrane of E. coli, and the OmpA fragment 
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was five of the eight membrane spanning domains, which left the soluble, periplasmic 
protein β-lactamase exposed extracellularly and active. 
 
FIGURE 1.5.  SCHEMATIC REPRESENTATION OF THE ORIGINAL LPP-OMPA-β-
LACTAMASE SURFACE DISPLAY SYSTEM (Francisco et al. 1992). 
 
Later, the Lpp-OmpA system was used to display an scFv on the surface of E. coli 
and showed enrichment by FACS of cells expressing the scFv versus control cells by a 
factor of greater than 100,000 using two rounds of sorting (Francisco et al. 1993).  This 
system was subsequently used to select for an enhanced binding antibody fragment to the 
hapten digoxin.  In this study, Patrick Daugherty in our laboratory was able to select an 
antibody fragment from a library of variants that bound with three-fold better affinity 
than the wild type scFv 26-10 (Daugherty et al. 1998).  Although this system was 
successful in its selection for hapten binders, the presence of lipopolysaccharides (LPS) 
and other moieties on the outer membrane interfered with protein-protein interactions and 
limited the size of antigens that could be used in this selection system (Chen and 




1.3.4.2 Periplasmic Expression with Cytometric Screening 
In an effort to circumvent challenges associated with Lpp-OmpA display, a 
“displayless” system was developed.  Periplasmic Expression with Cytometric Screening 
(PECS) utilized soluble expression of scFvs into the periplasm with a pelB leader 
sequence coupled with treatment of the cells to allow diffusion into the periplasm of 
fluorescently labeled antigen up to approximately 10 kDa in size while still maintaining 
the viability of those cells (Chen et al. 2001).  Another strength of this system was that no 
cloning manipulations were required for soluble expression of scFv after isolation of 
improved variants.  However, while diffusion of proteins up to 10 kDa in size was 
permitted, screening against larger proteins was still not feasible because the outer 
membrane was acting as a semi-permeable dialysis membrane; treatment to enlarge the 
pores to allow larger antigens access would permit scFv to escape as well.  Therefore, 
further effort was commenced to create a display system that could allow screening 
against proteins of great size. 
 
1.3.4.3 Anchored Periplasmic Expression 
The next evolution in gram negative display and selection technology was 
reported by Barrett Harvey in our laboratory in 2004.  First, an N-terminal sequence of 
six amino acids from the native lipoprotein A (NlpA) was placed on the scFv to direct 
lipidation and subsequent display on the periplasmic side of the inner membrane.  This 
was followed by disruption of the outer membrane using Lysozyme and EDTA in Tris-
Sucrose buffer to create so-called spheroplasts, allowing very large proteins that were 
fluorescently labeled access to the scFvs displayed on the inner membrane.  Sorting of 
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these samples of spheroplasts followed by recovery of the scFv genes by PCR meant that 
the viability of cells after labeling and sorting was no longer a determinant for recovery 
of successful binders.  Repeated rounds of cloning, sorting, and recovery PCR could be 
carried out to provide desired enrichment of the library.  By removing the outer 
membrane and the LPS associated with it, much larger protein antigens (with molecular 
weight >240 kDa) were able to freely associate with displayed scFv.  Additionally, 
screening within the periplasmic space resulted in increased protein levels when the 
isolated variants were placed in vectors utilizing pelB leader sequences for soluble 
periplasmic expression.  This system produced a scFv variant that bound to protective 
antigen (PA) of Bacillus anthracis at 35 pM, a greater than 200-fold enhancement of 
affinity from the parental scFv (Harvey et al. 2004).  In addition to affinity maturation, 
this technology has also been used to produce a two-hybrid system(Jeong et al. 2007), 
selection of intrabodies in a reducing periplasmic space (Seo et al. in press), and isolation 








1.3.4.4 Full IgG Display and Screening 
Another advance in screening technologies is the use of full IgG in a screening 
system.  All previous antibody display and screening technologies discussed have 
employed antibody fragments.  However, it is not clear that an antibody variant selected 
in the screening format as a fragment will translate to a highly expressing, well folded 
full IgG.  The screening system developed by Yariv Mazor in our laboratory utilizes full 
IgG expression and assembly in the periplasmic space of E. coli with the display system 
inspired by inner membrane anchoring similar to APEx.  IgG expression was elicited 
from a dicistronic operon under the control of an inducible promoter, while the anchoring 
protein, a fusion of the NlpA anchoring sequence and the IgG binding ZZ domain, were 
expressed from a different inducible promoter.  The ZZ domain is a dimeric analog of 
Staphylococcus aureus Protein A (Nilsson et al. 1987).  In this system, the NlpA-ZZ 
fusion protein is anchored into the periplasmic side of the inner membrane and captures 
correctly assembled IgG.  Lysozyme-EDTA treatment removes the outer membrane, and 
the spheroplasts are incubated with fluorescently labeled antigen and subjected to FACS.  
PCR recovery of the IgG variable genes is carried out, and the cycle of screening is 
continued until sufficient enrichment is observed.  The vector housing the desired IgG 
gene can be utilized for soluble expression in E. coli simply by not inducing the NlpA-ZZ 
fusion construct.  This display system was utilized to recover several IgG binders to PA 
of B. anthracis from a murine immune library extracted from an immunized mouse 
(Mazor et al. 2007). 
 
1.4 DIVERSITY 
Regardless of the display system used for screening, some method of creating 
genetic diversity must be used to allow high affinity antibody fragments to be isolated.  
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Extremely large naïve libraries mimicking the diversity of the natural immune system 
have been created and utilized with phage display to produce antibodies against many 
antigens (De Lorenzo et al. 2002).  Another method is to create a biased immune library 
by immunizing an animal with the antigen of choice, then isolating lymphocytes and 
harnessing the diversity of antibodies produced during the animal’s immune response 
(Hayhurst et al. 2003).  These systems are both useful for isolating novel binders to a 
given antigen as an initial step in antibody engineering.  However, once an initial 
antibody has been isolated, new methods for introducing diversity are needed to continue 
progress toward engineering ultra-high affinity antibodies. 
 
1.4.1 Error-Prone PCR 
One of the most common methods for introducing diversity into gene sequences is 
error-prone PCR.  Because of the ubiquity of PCR in molecular biology and the ease with 
which it is carried out, it has become quite commonplace to use for the creation of 
libraries.  Error-prone PCR takes advantage of conditions that lead to a relatively high 
error rate of Taq polymerase.  Several groups have published studies that have 
systematically looked at various conditions to reduce the apparent bias of polymerases to 
make certain base misincorporations while increasing the overall mutation rate (Cadwell 
and Joyce 1992; 1994; Fromant et al. 1995).  The most common method is to manipulate 
dNTP concentrations and supplement MgCl2 with MnCl2 to increase the promiscuity of 
Taq polymerase.  This methodology will introduce mutations within the bounds of the 
two primers used for PCR, so very wide regions can be covered, up to an entire gene.  
However, the ability to sample sequence space across large regions is tempered by the 
likelihood that complete accessibility to all other 19 amino acids is not probable from a 
given codon.  Because error rates associated with these libraries are generally in the 1-2% 
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range, the chance of having two or three base changes side by side in a give codon are 
prohibitively small, thus protein space is not sampled completely at individual codons.  In 
cases where smaller regions of a protein would benefit from being sampled more 
exhaustively in protein space, another method is needed to introduce diversity. 
 
1.4.2 Saturation Mutagenesis 
A complementary method to error-prone PCR, saturation mutagenesis, has the  
ability to introduce complete diversity at a given codon (Arkin and Youvan, 1992).  PCR 
is utilized to introduce primers that contain degenerate codons, most commonly NNK or 
NNS (N=A, G, C, or T; K=G or T; S=C or G), at specified locations within a gene 
(Varadarajan et al. 2008).  Generally, overlap PCR is used because it allows multiple 
locations to be randomized simultaneously.  While sampling of sequence space is 
complete for each randomized codon, the number of codons that can be completely 
randomized should be limited to four or five for a given library if the complete sequence 
space is to be covered.  For example, a library of five NNS codons already contains a 
diversity at the DNA level of more than 3x107 possible variants, which can be difficult to 
cover using standard molecular biological techniques.  Other studies have recommended 
different degenerate codons for use, such as NDT (D=A, G, or T;(Reetz et al. 2008).  
Although it does not cover all 20 amino acids in its diversity, the utility of such a codon 
is that it contains twelve codons that each code for a different amino acid.  Protein 
engineering studies based upon libraries utilizing the NDT codon allowed the isolation of 
a significantly higher number of positive variants from a given library when compared to 
a similar NNS library.  While this degenerate codon will certainly allow more residues to 
be covered in sequence space with a library of equivalent size, coverage of the complete 




To aid in the placement of diversity for the creation of more effective libraries, 
fundamental characterization of the system can provide a starting point by identifying key 
features of the protein in question.  In systems where antibody fragments interact with 
protein antigens, X-ray crystallography is the primary method used to reveal exacting, 
highly accurate detail within these complexes.  While the process yields structural data 
when finished, it begins with the expression and purification of the proteins of interest.   
 
1.5.1 Expression and Purification of Antibody Fragments 
For our purposes, protocols for expression and purification of antibody fragments 
have become quite refined.  The use of gene construction via PCR allows facile 
construction of an antibody fragment, and there are numerous vectors for cytoplasmic or 
periplasmic expression.  Expression in the periplasm is preferred, as removal of the outer 
membrane followed by immobilized metal affinity chromatography (IMAC) reproducibly 
yields highly active, relatively pure protein.   
If extremely high purity is needed, then isolation of protein by IMAC often 
requires additional purification.  Chromatographic systems utilizing Fast Performance 
Liquid Chromatography (FPLC) are among the most powerful methods of separation.  
Size exclusion chromatography (SEC) or ion exchange chromatography (IEC) can 
provide a platform for separation of protein in this setting.  IEC is useful when the 
isoelectric point (pI) of the protein of interest is separated from the pI’s of contaminant 
proteins by one pH unit or more.  IEC can be employed by utilizing a column with either 
an anionic or cationic matrix that will nonspecifically bind protein based on electrostatic 
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attraction.  The mixed protein sample can be bound to the appropriate column matrix by 
injection into the column, and protein can be eluted selectively as a salt gradient is 
applied to the column.   
If the properties of proteins in the milieu preclude use of IEC, then SEC can 
usually be employed.  This methodology employs a column packed with very small beads 
that have pores of a defined size.  Proteins injected into this column and subjected to a 
constant flow rate will separate based upon size because of the ability of smaller proteins 
to reside in the pores for greater amounts of time.  Thus, larger proteins elute first, 
followed by smaller proteins.  In general, protein obtained by IMAC can be purified to 
very high purity using SEC. 
 
1.5.2 Crystallographic Screening 
Once pure protein has been acquired, it is necessary to ascertain what conditions 
are favorable for crystallization of the protein of interest.  The first consideration is the 
method of crystallization that will be used.  Two of the most commonly used 
methodologies are vapor diffusion (by hanging or sitting drop) and microbatch.  In 
typical vapor diffusion screening, a large volume (400-600 µL) of a solution of buffer, 
salts, and/or precipitant is sealed into a closed well with a drop (typically 1-2 µL) of a 1:1 
mixture of concentrated protein with the screening solution sitting on a pedestal (sitting 
drop) or suspended from a slide cover (hanging drop).  As time passes, water evaporates 
and diffuses out of the drop and into the air and reservoir well solution until the 
concentration of salt or precipitant comes to equilibrium between the reservoir well and 
the drop; this causes concentration of the protein in the drop, and if supersaturation 
occurs in a solution that is amenable to ordered formation of a reproducible lattice, then 
















FIGURE 1.7.  DIFFERENT METHODOLOGIES FOR CRYSTAL SCREENING.  (A) Sitting 
drop vapor diffusion, (B) Hanging drop vapor diffusion, (C) Microbatch, (D) Microbatch 
diffusion.  Adapted from (McPherson 1999). 
 
Microbatch is another very simple method of screening for crystallization 
conditions.  In this system, a small drop of concentrated protein solution is mixed in a 
well with another small drop of the screening solution consisting of buffer, salts, and/or 
precipitant under a large volume of paraffin oil (D'Arcy et al. 2004).  The paraffin oil 
provides a seal to prevent evaporation of liquid from the drop, so crystallization occurs if 
supersaturation occurs when the small drops mix.  A variation of this technique, known 
as microbatch diffusion, has been developed which is a fusion of the concepts of 
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microbatch and vapor diffusion (D'Arcy et al. 2003).  In this methodology, a screen is set 
up as for microbatch, except that a 1:1 mixture of paraffin oil and silicon fluid is used.  
The silicon fluid allows the diffusion and subsequent evaporation of water away from the 
drop, thus providing simultaneous concentration of the protein and precipitant that can 
lead to crystal formation. 
 
1.5.3 Crystal Screens 
Once a screening format is chosen, then the conditions to test during screening 
must be considered.  Conditions among those known to affect crystallization are pH, 
precipitant, temperature, and additives.  There are, of course, a great many other factors, 
but it is generally inconvenient to begin screening beyond these initial variables (Kundrot 
2004).  As it is, one could create many more conditions with only these four variables 
than is feasible to cover in a screen for crystallization of a protein.  Because of this, much 
effort has been devoted to determining the most efficient set of experiments to discover 
crystallization conditions for a given protein.  While diffraction quality crystals might be 
formed from the initial screen, its true importance lies in uncovering those small regions 
in “condition space” where crystal growth is likely; more refined screens can be 
constructed around conditions of initial success to enhance quality of crystals.   
A variety of initial screens have been developed using different designs for the 
mixing of reagents such as random screens (Shieh et al. 1995), grid screens (McPherson 
1989), incomplete factorial screens (Carter and Carter 1979), footprint screens (Stura et 
al. 1992), and sparse matrix screens (Jancarik and Kim 1991).  These screens generally 
are using reagents that had success inducing crystallization of previous proteins, so the 
selection of these reagents is based upon their historical effectiveness, not their actual 
efficiency of stimulating crystal growth.  While there exists an assortment of initial 
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screens, studies indicate that an average lower limit of success is 2%, or 1 crystal 
observed in 50 screened conditions (Segelke 2001).  In this case, the probability of 
observing at least one “hit” in screening when using three commercially available screens 
of 96 conditions each is 99.7% (P = 1 - 0.98288).  Even assuming a much more pessimistic 
success rate of 0.2%, or 1 “hit” in 500 conditions, the probability is still 43.8% (P = 1 – 
0.998288).  Therefore, the most important factor in discovering crystallization conditions 
is the number of different conditions attempted (Kundrot 2004).  To amplify this point, a 
high throughput crystallization facility that utilizes a 1,536 condition screen reported that 
although most proteins deliver 50 or more “hits,” there have been several cases where 
only one condition in 1,536 produced a protein crystal (Luft et al. 2003). 
 
1.5.4 “Throughput” in Crystallographic Screening 
Because increasing the number of conditions screened increases the chances of 
success, consideration of the level of throughput for a crystallographic endeavor is 
warranted.  Traditionally, screening was carried out in low-throughput fashion, as every 
event in the process of crystal screening was performed by hand.  While low-throughput 
methodology has certainly been successful historically, the use of robotics to automate 
certain aspects of the screening process has aided in the efficiency of man hours spent 
searching for “hits.”  High-throughput screening utilizes automation at every point in the 
process: dispensing of crystal trays, visualization scoring, creating refined screens, and 
screen mixing.  These systems are typically made up of several robots and are extremely 
costly, making them available only to those facilities that are intensely dedicated to 
producing great numbers of crystal structures (Kundrot 2004).  Between these two 
extremes, medium-throughput screening generally employs some degree of automation in 
conjunction with some manual work.  Typically, setup of protein screening plates is 
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automated by a single instrument, while scoring of conditions for crystal growth, and 
designing and preparing fine screens are done by hand.  This level of automation is 
quickly being adopted as the standard by crystallography labs far and wide, as robotics 
can prepare in minutes what takes hours for an experienced technician to prepare by 
hand. 
Another benefit of automation in the setup of crystal screening trays is 
miniaturization.  When preparing trays by hand, it is typical to prepare 2 µL drops (1 µL 
of a 10 mg/mL protein solution added to 1 µL of screen) because manual micro-pipettors 
are not very precise below 1 µL.  However, with robotics that can reliably deliver 100 nL 
(0.1 µL), utilizing 0.2 µL drops for screening becomes feasible.  This results in the ability 
to cover 10-fold more conditions using the same amount of protein.  For costly, difficult 
to purify, or poorly expressing proteins, this reduction in the requirement of sample can 
be the difference between initiating screening or abandoning the effort altogether. 
A number of systems are available for these purposes, and they vary by their 
functionalities.  Most systems are capable of preparing either vapor diffusion or 
microbatch screens.  Commercially available instruments currently include the Art 
Robbins Instruments Phoenix, the Matrix-Drop Maker Hybrid™ from Emerald 
Biosystems, the Genomic Solutions® Honeybee, the Oryx line of robots from Douglas 
Instruments, and the Fluidigm Topaz®. 
 
1.6 ANTHRAX 
Bacillus anthracis, a gram positive, sporulating bacterium, is the causative agent 
of the zoonotic disease anthrax. Three forms of the disease occur in humans, cutaneous, 
gastrointestinal, and inhalational.  Cutaneous anthrax is the most common form, and is 
rarely fatal.  Gastrointestinal and inhalational anthrax are far less common and far more 
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fatal.  Because of this fatality combined with the fact that anthrax spores are resistant to a 
wide variety of environmental conditions, it has long been feared as an agent of 
biowarfare.  There is evidence of nations cultivating B. anthracis for use as an offensive 
weapon, and the Anthrax letter attacks of 2001 revealed the significant terror incited by 
even a relatively small scale attack. 
Anthrax virulence is mediated through two independent mechanisms, its poly-
gamma-D-glutamic acid capsule, and soluble, excreted binary toxin.  Three proteins are 
involved in the toxic action, protective antigen (PA), lethal factor (LF), and edema factor 
(EF).  PA is an 83 kDa protein that binds with high affinity to the mammalian cellular 
receptors ATR/TEM8 (Bradley et al. 2001) and CMG2 (Scobie et al. 2003; Scobie and 
Young 2005).  Cleavage by furin protease to a 63 kDa form and heptamerization leads to 
the binding of LF or EF (Young and Collier 2007).  Clathrin-mediated endocytosis of the 
PA/LF/EF complex provides the route of entry, which followed by acidification of the 
resulting endosome that, in turn, elicits a conformational change in heptameric PA. The 
result is that a pore is formed by PA that delivers LF and EF into the host cell cytoplasm 
to carry out their functions.  EF is an adenylate cyclase, and LF is a protease that 
inactivates mitogen activated protein kinase kinases (MAPKKs) and thus interferes in 
their signaling pathways. 
PA is a protein 735 amino acids in length that is composed of four domains, 1-4 
from the N- to C-terminus (Petosa et al. 1997).  Domain 1 is 258 residues long and 
contains the site of furin cleavage at amino acid 167.  Domain 2, which is 238 residues in 
length, is responsible for pore formation and also makes partial contact with the cellular 
receptor when PA initially binds to ATR or CMG2 (Santelli et al. 2004).  Domain 3 is a 
109 amino acid region that is thought to be responsible for heptamerization of PA63 
(Mogridge et al. 2001).  Domain 4 is the C-terminal 139 amino acids of PA, and it is 
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responsible for a majority of binding to CMG2 or ATR (Singh et al. 1991; Santelli et al. 
2004). 
There are numerous examples of antibodies that have been generated to various 
epitopes of the toxin components that have neutralizing effects (Little et al. 1988; Little 
et al. 1997; Cirino et al. 1999; Maynard et al. 2002; Wild et al. 2003; Brossier et al. 
2004; Harvey et al. 2004; Karginov et al. 2004; Sawada-Hirai et al. 2004; Wang et al. 
2004; Cui et al. 2005; Huber et al. 2005; Hull et al. 2005; Laffly et al. 2005; Mohamed et 
al. 2005; Subramanian et al. 2005; Chen et al. 2006; Gubbins et al. 2006; Paddle et al. 
2006; Rivera et al. 2006; Vitale et al. 2006; Albrecht et al. 2007; Kelly et al. 2007; Pelat 
et al. 2007; Staats et al. 2007; Steiniger et al. 2007; Zhou et al. 2008), and several of 
these are in clinical trials.  In fact, one has even been utilized to treat inhalational anthrax 
in humans (Walsh et al. 2007).  Many of these antibodies elicit their neutralizing action 
by preventing PA from interacting with the mammalian cellular receptors.  It is clear that 
in order to effectively prevent intoxication in vivo, the affinity of the antibody for PA 
must be stronger that the affinity of PA for its cellular receptors (Maynard et al. 2002).  
One of the first well-characterized antibodies that was shown to target PA while 
interrupting interaction with its cellular receptors was 14B7 (Little et al. 1988).  Phage 
display and Anchored Periplasmic Expression (APEx) were utilized to produce the high 
affinity 14B7 variants called 1H (Maynard et al. 2002) and M18 (Harvey et al. 2004) 
respectively.  These antibodies have been shown to be protective in various assays 
(Maynard et al. 2002; Mabry et al. 2005).  Affinities for the 14B7 family of antibodies 
are as follows: 4nM (14B7), to 250pM (1H) and 35pM (M18). 
Previous work has revealed the structures of monomeric and heptameric PA 
(Petosa et al. 1997), LF (Pannifer et al. 2001), as well as the interaction of PA with 
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CMG2 (Santelli et al. 2004).  These structures, in combination with other molecular 
studies have augmented our knowledge of the intoxication processes of B. anthracis.   
Alanine scanning studies have initiated our understanding of the interactions that 
PA has with the 14B7 family of neutralizing antibodies.  The alanine scanning indicated 
that 14B7 and the cellular receptors had overlapping, but non-identical, epitopes on PA.  
Consequently, PA variants that retained near-wild type toxicity while abrogating 14B7 
binding were found (Rosovitz et al. 2003).  These variants, chiefly L685A and Y688A, 
revealed potential circumventions to successful therapy in the event of malicious intent to 
alter the toxin. 
1.7 PROJECT BIOSHIELD 
 After the Anthrax letter attacks of 2001, a great deal of research was conducted to 
discover novel inhibitors of anthrax toxin.  Additionally, congress authorized the creation 
of Project Bioshield in 2004.  This initiative was initially placed under the purview of the 
Department of Health and Human Services.  Its scope was to accelerate research and 
development of countermeasures to chemical, biological, radiological, and nuclear 
(CBRN) threats, as well as to acquire therapeutics for these contingencies for addition to 
the Strategic National Stockpile (SNS).  This legislation allocated up to $5.6 billion over 
ten years for this endeavor.  Contracts have been awarded for anthrax vaccine, anthrax 
therapeutics, botulinum antitoxin, smallpox vaccine, and agents to treat nuclear and 
radiological side effects (Russell 2007).   
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1.8 PROJECT AIMS 
The focus of this research is to uncover the structure of the interaction of PA with 
a member of the 14B7 neutralizing antibody family, and to use that information to allow 
engineering of the antibody family for various applications. 
Chapter 2 focuses on the X-ray crystallographic studies that reveal the structure of 
the antibodies in the 14B7 family as well as the complex of the ultra-high affinity variant 
M18 with PA domain 4.  This work exposes the mechanism of interaction of this 
neutralizing antibody family with the anthrax toxin, and it increases understanding of the 
basis of affinity maturation in this system. 
Chapter 3 utilizes this information to create libraries with highly focused diversity 
to engineer a member of the 14B7 antibody family to achieve better binding to the 
Y688A variant of PA, a previously intractable problem for in vitro evolution.  This 
appears to represent a generalizable solution to the engineering of the 14B7 family of 
antibodies for altered forms of the toxin.   
Chapter 4 focuses on the effort to create a photoresponsive antibody.  Using the 
M18—PA interaction as a model system, this endeavor works through two platforms for 
affecting antibody affinity using an appendage that is reversibly responsive to light.   
Chapter 5 describes an unrelated project, which was to confirm the existence of a 
proposed RNA thermosensor in the 5’ untranslated region of LcrF from the pathogenic 
bacterium Yersinia pestis, the causative agent of plague. 
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 CHAPTER 2 
Crystal Structure of the Engineered Neutralizing Antibody M18 
Complexed to the Anthrax Protective Antigen (PA) 
 
This chapter is a manuscript that has been submitted for publication.  Jennifer A. 
Maynard prepared 14B7* protein and crystallized 14B7*.  Clinton E. Leysath prepared 
all other proteins and crystallized 1H, M18, and the M18-PAD4 complex; he was also 
responsible for solving the structure of 1H, carrying out the kinetic studies, and co-
authoring of the manuscript.  Arthur F. Monzingo was responsible for solving the 
structures of 14B7*, M18, and the M18-PAD4 complex; he also created the figures and 
co-authored the manuscript.  Jon D. Robertus, Brent L. Iverson, and George Georgiou 
were all responsible for co-authoring of the manuscript. 
2.1 INTRODUCTION 
Anthrax remains a significant threat as a biological weapon due in large part to its 
ease of both large-scale manufacture and weaponization in the spore state.  Following 
spore inhalation, anthrax is lethal in humans due to the combined actions of secreted 
toxins (Moayeri and Leppla 2004; Young and Collier 2007).  An effective 
countermeasure strategy requires an effective anti-toxin therapy (Little et al. 1988; Cirino 
et al. 1999; Sellman et al. 2001; Maynard et al. 2002; Wild et al. 2003; Brossier et al. 
2004; Harvey et al. 2004; Sawada-Hirai et al. 2004; Turk et al. 2004; Shoop et al. 2005; 
Subramanian et al. 2005; Chen et al. 2006; Jiao et al. 2006; Rivera et al. 2006; Albrecht 
et al. 2007; Pelat et al. 2007; Steiniger et al. 2007) to be used in combination with 
antibiotics, or as a stand alone treatment of an antibiotic resistant strain of anthrax 
(Mohamed et al. 2005). 
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We, and others, have been developing a combination prophylactic-post exposure 
therapeutic for anthrax based on an engineered antibody against the anthrax protective 
antigen (PA) toxin (Little et al. 1988; Little et al. 1997; Cirino et al. 1999; Maynard et al. 
2002; Wild et al. 2003; Brossier et al. 2004; Harvey et al. 2004; Karginov et al. 2004; 
Sawada-Hirai et al. 2004; Cui et al. 2005; Mohamed et al. 2005; Subramanian et al. 
2005; Chen et al. 2006; Rivera et al. 2006; Vitale et al. 2006; Albrecht et al. 2007; Kelly 
et al. 2007; Pelat et al. 2007; Steiniger et al. 2007).  Briefly, the PA toxin facilitates host 
cellular targeting and transport of the lethal factor (LF) and edema factor (EF) into the 
cytoplasm.  LF is a protease that targets mitogen-activated protein kinase kinases 
(MAPKKs).  EF is an adenylate cyclase.  The presence of cytoplasmic LF and EF trigger 
a series of biochemical events that lead to anthrax symptoms and eventually to death 
(Moayeri and Leppla 2004; Young and Collier 2007).   
The intoxication process is initiated when monomeric PA83 is processed by host 
proteases to form the PA63 fragment, which binds as a heptamer with high affinity to the 
TEM8 and CMG2 cellular receptors on host cells such as macrophages.  High affinity 
antibodies that block the PA-receptor interaction are effective post-exposure treatments 
for anthrax in animal models (Little et al. 1997; Karginov et al. 2004; Cui et al. 2005; 
Vitale et al. 2006; Kelly et al. 2007).  In addition, the same anti-PA antibodies can serve 
as prophylactics to prevent infection from spore inhalation, although the mechanism of 
prophylaxis is not well understood (Kobiler et al. 2002; Cote et al. 2005; Mabry et al. 
2005; Mohamed et al. 2005; Peterson et al. 2006). 
The 14B7 murine monoclonal antibody (KD = 4.3 nM), originally developed at 
USAMRIID (Little et al. 1988), was shown to delay time-to-death following exposure to 
anthrax spores in a guinea pig model (Little et al. 1997).  14B7 is known to recognize the 
receptor-binding region of PA and thereby block PA-host cell interactions (Rosovitz et 
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al. 2003).  Originally, we used phage display to isolate an affinity enhanced version of 
14B7 called 1H, exhibiting a KD of 250 pM (Maynard et al. 2002).  1H was shown to 
prevent PA-LF induced death in a rat model and in whole IgG format it is currently in 
clinical development.  The approximately 20-fold affinity enhancement of 1H compared 
to 14B7 is achieved with two mutations, Q55L and S56P, in CDR L2.  Subsequently, we 
used our bacterial display/FACS technology, referred to as APEx, to engineer an even 
higher affinity variant of 14B7 called M18 (Harvey et al. 2004).  M18 has 10 mutations 
(light chain I21V, L46F, S56P, S76N, Q78L, and L94P; heavy chain S30N, T58S, K65E, 
and T69I) and exhibits a KD = 35 pM.   We sought to use crystallographic studies to 1) 
reveal the structural details of the interactions between the 14B7 family of antibodies 
with PA and 2) to help elucidate how the mutations in 1H and M18 serve to enhance 
overall antibody affinity.  
Crystallographic studies of antibody fragments in complex with a protein antigen 
have been ongoing for more than 25 years.  A large number of these studies have been 
carried out on lysozyme variants and their antibodies, utilizing the propensity of 
lysozyme to crystallize to enable recovery of crystals of the complex (Amit et al. 1986; 
Padlan et al. 1989; Braden et al. 1994; Braden et al. 1995; Davies and Cohen 1996; Li et 
al. 2003).  Other studies have targeted antibodies in complex with influenza 
neuraminidase (Colman et al. 1987), cytochrome C (Mylvaganam et al. 1998), tissue 
factor (Huang et al. 1998), outer surface proteins of Borrelia bergdorferi (Li et al. 1997), 
staphylococcal nuclease (Bossart-Whitaker et al. 1995), vascular endothelial growth 
factor (Muller et al. 1998), GP120 of HIV (Zhou et al. 2007), a phosphocarrier protein of 
E. coli (Prasad et al. 1998), a myelin oligodendrocyte glycoprotein (Breithaupt et al. 
2003), the epidermal growth factor receptor (EGFR) family (Cho et al. 2003; Li et al. 
2005), the CD3 epsilon gamma heterodimer (Kjer-Nielsen et al. 2004), the T-cell 
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costimulatory protein CD28 (Evans et al. 2005),  the severe acute respiratory syndrome 
(SARS) coronavirus receptor binding domain (RBD) (Prabakaran et al. 2006), the 
poxvirus L1 protein (Su et al. 2007), the malaria apical membrane antigen 1 (AMA1) 
(Igonet et al. 2007), allergens (Li et al. 2008), human prostate-specific antigen (PSA) 
(Menez et al. 2008), dengue viral envelope glycoprotein (Lok et al. 2008), the 
membrane-type serine protease 1 (Farady et al. 2008), Ebola glycoprotein (Lee et al. 
2008), idiotype-anti-idiotype interactions (Fields et al. 1995), and autoimmune disease 
interactions of antibodies to other antibodies (Corper et al. 1997). 
Generally, antibodies to protein antigens target a discontinuous epitope on the 
antigen (Padlan et al. 1989).  It is also common for all 6 complementarity-determining 
regions (CDRs) of the antibody to interact with the antigen (Padlan et al. 1989; Huang et 
al. 1998; Mylvaganam et al. 1998; Prasad et al. 1998), and on occasion, framework 
residues make contact as well (Padlan et al. 1989).  The interaction surface is generally a 
flat, rectangular area (Amit et al. 1986), though there are exceptions (Bossart-Whitaker et 
al. 1995).  Shape complementarity along the interaction surface appears to be important 
(Muller et al. 1998; Mylvaganam et al. 1998; Li et al. 2003) and a nonpolar “hotspot” is 
generally found to be an energetically important part of the complex.  The degree of 
solvation at the interface can vary (Braden et al. 1994), and bound water molecules may 
add hydrogen bond interactions (Braden et al. 1995).  However, there are also occasions 
where there are voids that remain unsolvated (Braden et al. 1994).  A study of the affinity 
maturation of antibodies to lysozyme revealed that improved shape complementarity and 
burial of nonpolar surface at the expense of polar surface were generally correlated with 
increased affinity (Li et al. 2003).  In addition, structural studies with small molecule 
haptens have indicated that affinity maturation via somatic mutation might involve 
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freezing out complementary conformations of CDR loops, involving mutations in 
residues that can be up to 15 Å away (Wedemayer et al. 1997). 
Here we report the crystal structure of M18 in complex with domain 4 of PA and 
the crystal structures of high affinity antibodies 14B7, 1H, and M18.  The M18-PA 
complex offers a detailed explanation for the neutralizing activity of the 14B7 family of 
antibodies, and also provides some insight into the affinity enhancements seen with 
engineered versions of 14B7.  In the future, the M18-PA complex structure will serve as 
a useful reference to target specific regions of 14B7 family antibodies to make even 
higher affinity variants, and for mutagenesis in the event a non-neutralizing variant of PA 
is encountered through either deliberate or natural variation. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Protein purification 
M18, 1H, and 14B7* scFv’s were cloned into the periplasmic expression vector 
pAK400.  Protein was prepared as described previously (Hayhurst et al. 2003).  See 
Figure 2.1 for their sequences, as well as that of the parent monoclonal antibody 14B7.  
Briefly, a pelB leader sequence was utilized to express protein into the periplasm of E. 
coli strain Jude-1, and osmotic shock followed by immobilized metal affinity 
chromatography was used for initial purification.  Size exclusion chromatography 
(AKTA FPLC and Superdex 200 column, GE Healthcare) allowed isolation of 
monomeric scFv.  Monomeric scFv was then digested overnight at 4ºC with 
Carboxypeptidase A (Calbiochem, San Diego, CA, 1:100 mass ratio, protease:scFv).  A 
second round of FPLC was followed by concentration to 10 mg/ml (Amicon Ultra 15, 
10000 MWCO) into 1xHBS-EP (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 
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0.005% Polysorbate-20).  Full-length Anthrax Protective Antigen (PA83) was purchased 
from List Biological Labs (Campbell, CA), resuspended at 1 mg/ml, and subjected to size 
exclusion FPLC.  Protein was concentrated to 10 mg/ml into 1xHBS-EP. 
 
FIGURE 2.1 - SEQUENCE ALIGNMENT OF SCFV 14B7, 14B7*, 1H, AND M18.  In these 
scFv constructs, the light chain precedes the heavy chain in the sequence, linked by a 
glycine-rich linker region.  Framework and complementarity-determining regions are 
indicated as well as secondary structure.  Differences from the 14B7 sequence in the 
framework regions are highlighted in gray; differences in the CDRs are highlighted in 
black.  This figure was made using ALSCRIPT. 
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2.2.2 Site-directed mutagenesis and kinetic studies 
Mutant scFv’s 14B7-L46F and M18-F46L were constructed using the 
QuikChange protocol (Stratagene, La Jolla, CA).  After protein expression, kinetic 
studies were carried out using a Biacore 3000 (Biacore, Inc., Piscataway, NJ).  Briefly, 
amine coupling chemistry was used to immobilize 750 RU of either PA83 or BSA 
(control) to a CM5 chip.  Samples were injected for 60 seconds at 100 µl/min in 1 x 
HBS-EP and allowed to dissociate for 15 minutes at the same flow rate.  Regeneration of 
the flow cells was accomplished using a 30 second injection of 4 M MgCl2 at 100 µl/min. 
 
2.2.3 Crystallization and data collection 
The 14B7* scFv protein was crystallized at room temperature in sitting drops 
from mixtures containing a one-to-one ratio of antibody solution (15 mg/mL) and 
reservoir solution [20% (w/v) PEG 4000, 0.1 HEPES, pH 7.5, 10% iso-propanol].  The 
higher affinity variants 1H and M18 were crystallized under the same conditions at 4°C.  
Prior to data collection, crystals were transferred to a cryoprotectant solution (the 
reservoir solution containing 25% glycerol) for 1-5 seconds.  The 14B7* crystal was 
flash-frozen directly in the cold nitrogen stream on the goniostat.  The 1H and M18 
crystals, mounted in a cryoloop (Hampton Research, Laguna Niguel, CA), was frozen by 
dipping in liquid nitrogen and placed in the cold stream on the goniostat.   
A mixture of PA83 and M18 with a 1:1.1 molar ratio was used to screen for 
crystallization conditions by the sitting drop method.  Eleven months after the 
crystallization conditions were set up, a crystal was found in a condition at 4ºC with the 
reservoir solution 10% PEG 20,000, 0.05 M Tris-HCl, pH 7.5.  Prior to data collection, 
crystals were transferred to a cryoprotectant solution (6% PEG 20,000, 0.05 M Tris-HCl, 
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pH 7.5, 25% glycerol) for 1-5 seconds.  The complex crystal, mounted in a cryoloop, was 
frozen by dipping in liquid nitrogen and placed in the cold stream on the goniostat.   
X-ray diffraction data from the 14B7* crystal were collected at 100 K on 
beamline 8.2.1 of the Advanced Light Source (Lawrence Berkeley National Laboratory).  
Diffraction data of the 1H, M18, and complex crystals were collected at 100 K on an 
RAXIS IV++ image plate detector (Rigaku, The Woodlands, TX) with X-rays generated 
by a Rigaku RU-H3R rotating anode generator operated at 50 mV, 100 mA.  Diffraction 
images were processed and data reduced using HKL2000 (Otwinowski and Minor 1997). 
 
2.2.4 Molecular replacement for the scFv’s 
The structure of the 14B7* scFv was solved by molecular replacement using the 
light chain of blood group A Fv (PDB accession code 1JV5) (Thomas et al. 2002) and the 
heavy chain of Fab17-IA (accession code 1FOR) (Liu et al. 1994) as search models; the 
structures were aligned with the EPMR (Evolutionary Protein Molecular Replacement) 
program (Kissinger et al. 2001).  An initial chain tracing was generated from the 
molecular replacement solution using ARP/wARP (Perrakis et al. 1997).  The structures 
of the 1H and M18 scFv’s were solved by molecular replacement using the 14B7* 
structure as the search model with the program MOLREP (Vagin and Teplyakov 1997). 
 
2.2.5 Molecular replacement for the Complex  
Crystal cell parameters of the complex crystal suggested that the asymmetric unit 
might contain two PA83-M18 complexes.  Molecular replacement searches using several 
programs and with various search models, including PA83 (PDB accession code 1ACC; 
Petosa et al. 1997), PA63, 14B7*, and individual PA domains, failed to find a solution.  
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Finally, a search using the program PHASER (McCoy 2007) with the single chain 
antibody 14B7* as a model gave a result that had a rotation function Z-score of 5.7 and a 
translation function Z-score of 5.9; the program authors have stated that scores of this 
magnitude may indicate a correct solution.  Subsequent searches with 14B7* found 
solutions for three additional molecules, with increasingly improved Z-scores.  Following 
that, solutions for the positions of four copies of PA domain 4 (PAD4) were determined.  
Examination of the packing of the four M18 scFv and four PAD4 molecules in the 
asymmetric unit showed that there were four essentially identical M18 scFv-PAD4 
heterodimers; this initial model had an R-factor of 32.6% suggesting that this was the 
correct molecular replacement solution.   
 
2.2.6 Structure determination and analysis 
Model building was carried out using O (Jones et al. 1991).  Refinement of 
models was performed with the Crystallography and NMR System (CNS) (Version 
1.1)(Brunger et al. 1998).  The structures of the scFv’s were refined using the slow-
cooling protocol.  For the 3.8 Å resolution complex structure, atomic positions were 
restrained by non-crystallographic symmetry and refined using conjugate gradient 
minimization.  Temperature factors for each residue in the complex were also refined.  
There were several rounds of refinement followed by manual rebuilding of the model.  
To facilitate manual rebuilding, a difference map and a 2Fo-Fc map, SIGMAA-weighted 
to eliminate bias from the model (Read 1986), were prepared.  5% of the diffraction data 
were set aside throughout refinement for cross-validation (Brunger 1993).  Computations 
and model building were carried out on Silicon Graphics Indy (Mountain View, CA), 
Gateway SB Select (Poway, CA), and HP Pavilion a1610n (Hewlett-Packard Co., Palo 
Alto, CA) computers.   
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Superpositions of protein molecules were done with O.  Model pictures were 
made using MOLSCRIPT, BOBSCRIPT, Raster3D, and PYMOL (DeLano Scientific, 
San Carlos, CA). 
 
2.3 RESULTS AND DISCUSSION 
2.3.1 X-ray structure determination 
The 14B7* scFv crystallized in space group P41212 with cell constants a = b = 
80.18, c = 67.83 Å and with one molecule per asymmetric unit, giving a Vm of 2.3 Å
3 / 
dalton.  The structure was solved by molecular replacement using the κ chain of the 
blood group A Fv (PDB accession code 1JV5) (Thomas et al. 2002) and the heavy chain 
of Fab17-IA (PDB code 1FOR) (Liu et al. 1994) as search models for the light and heavy 
chains, respectively.  Of known antibody structures, these two showed the highest 
sequence homology with 14B7*.  The final refined structure consists of residues 1-107 of 
the light chain and 4-118 of the heavy chain; it has an Rworking of 21.7% and an Rfree of 
23.6%, at a resolution of 1.3 Å. The 20 residue linker between the C-terminus of the light 
chain and the N-terminus of the heavy chain is not visible in electron density maps nor 
were residues 1- 3 and the C-terminal residue (119) of the heavy chain.  We assume the 
missing residues are all disordered.  The refined model includes 265 solvent molecules.  
A representative section of electron density is shown in Figure 2.2a. 
A Ramachandran plot shows 92.5% of residues in the most favorable region and 
7.0% in additional allowed space.  Light chain Thr 51, located on the CDR L2 loop, is 
found in an energetically disfavored conformation, stabilized by hydrogen bonds with 
neighboring residues.  This residue is also in this same disallowed conformation in both 




FIGURE 2.2 - ELECTRON DENSITY FROM A SIGMAA-WEIGHTED (READ 1986) 
2FO-FC MAP, CALCULATED WITH PHASES FROM THE FINAL REFINED MODEL.  These 
stereo maps are contoured at 1.0 . (a) 14B7*; (b) from the PAD4-M18 interface region 
around residue Y688 of PAD4. 
 
Crystals of the high affinity variant 1H, crystallized under the same conditions as 
14B7* but at 4°C, grew in the same crystal form as 14B7* but diffracted to only 2.8 Å.  
The structure was solved by molecular replacement using the 14B7* structure as the 
search model.  The final refined structure consists of residues 1-108 of the light chain and 
3-119 of the heavy chain and has an Rworking of 21.7% and an Rfree of 25.6%.  In addition, 
there is clear electron density for one leader residue preceding the N-terminus of the light 
chain, and this residue is included in the final model.  As with 14B7*, the 20 residue 
linker between the light and heavy chains was not visible in electron density maps.  A 
Ramachandran plot shows 88.4% of residues in the most favorable region and 11.1% in 
additional allowed space.  The refined model includes 16 solvent molecules. 
Crystals of the ultrahigh affinity variant M18 scFv were grown under the same 
conditions as 1H and diffracted to 2.0 Å.  Unlike 14B7* and 1H, the M18 scFv 
crystallized in space group P1 with cell constants a = 36.07, b = 54.21, c = 61.95 Å,  = 
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71.8°,  = 75.6°,and  = 71.3° and with two molecules per asymmetric unit, giving a Vm 
of 2.2 Å3 / dalton.  The structure was solved by molecular replacement using the 14B7* 
structure as the search model.  The final refined structure consists of residues of 1-108 of 
the light chain and 2-119 of the heavy chain and has an Rworking of 19.4% and an Rfree of 
22.9%.  In addition, there is density for two leader residues preceding the N-terminus of 
the light chain.  As with 14B7* and 1H, the 20 residue linker between the light and heavy 
chains was not visible in electron density maps.  A Ramachandran plot shows 88.2% of 
residues in the most favorable region and 11.3% in additional allowed.  The refined 
model includes 291 solvent molecules. 
The complex of M18 and the Anthrax Protective Antigen domain 4 (PAD4) 
crystallized in space group P21 with cell constants a = 48.94, b = 299.72, c = 68.95, and  
= 94.5º.  Four antigen-scFv complexes were found in the asymmetric unit, giving a Vm of 
3.1 Å3 / dalton.  The crystal diffracted to only 3.8 Å, but four-fold non-crystallographic 
restraints permitted the refinement of individual atomic positions and of group 
temperature factors for each residue.  The final refined structure has an Rworking of 23.2% 
and an Rfree of 27.6%.  Figure 2.2b shows electron density from a 2Fo-Fc map at the 
interface between PA domain 4 and both the H and L chains of M18.  Crystallographic 









Table 2.1.  Crystallographic Data 
 14B7* 1H M18 PAD4-M18 
Space group P41212 P41212 P1 P21 













# of molecules 
per asymmetric 
unit 
1 1 2 4 







Rmerge (%) 7.9 (46.6) 16.0 (39.0) 4.0 (10.7) 12.0 (28.3) 
<I/σI> 9.4 (4.5) 13.7 (5.2) 26.4 (7.4) 6.1 (3.7) 
Completeness 
(%) 99.1 (100.) 99.9 (99.3) 94.8 (92.4) 96.0 (91.6) 
Unique 
reflections 54,301 5839 26,245 18,357 
Redundancy 12.8 8.2 2.0 2.6 
# of residues 222 226 455 1485 
# of protein 
atoms 1704 1724 3521 11,546 
# of solvent 
atoms 265 16 291  
Rworking 0.216 0.217 0.194 0.232 





















Values in parentheses correspond to highest resolution shell 
 
As mentioned above, the asymmetric unit of the complex contains four PAD4-
M18 heterodimers.  In particular, each heterodimer is related to a second heterodimer by 
a non-crystallographic two-fold rotation with the dimer interface of this greater dimer 
involving principally -strands of the light chain 62-67 and 70-74.  The two greater dimer 
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particles in the asymmetric unit are, in turn, related by a rotation of 178° about an axis 
that is around 91° from the greater dimerization axis.  Contact between the greater dimer 
particles of the asymmetric unit involves a single PAD4 monomer in each. 
The four M18 molecules within the asymmetric unit are virtually identical.  As 
was observed in the structures of unbound 14B7*, 1H, and M18, electron density is 
observed for residues of the light chain and heavy chain but not for the 20 amino acids 
linking the C-terminus of the light chain to the N-terminus of the heavy chain in the scFv.  
In two of the M18 monomers, residues 1-119 of the heavy chain are observed while only 
heavy chain residues 2-119 can be seen in the other two monomers.   
The four PAD4 molecules within the asymmetric unit are also virtually identical 
with the largest differences seen in the N-terminal loop, residues 592-605.  This loop 
extends away from the rest of the molecule, and as a result, the crystal packing 
environment differs for each PAD4 monomer in the asymmetric unit producing subtle 
conformational differences.  There is also some variation in the PAD4 sequence length 
observed.  For three of the PAD4 monomers, density for residues 592-735 is observed, 
but for the fourth monomer, only residues 593-735 are seen. 
 
2.3.2 Comparison of the scFv structures 
The structures of the 14B7* scFv and the engineered variants 1H and M18 all 
show the expected typical immunoglobulin fold presenting a large binding surface 
formed by the CDRs.  The folds of the three scFv antibodies are virtually identical.  The 
rms distance between equivalent C positions of 14B7* and 1H is 0.24 Å, and similarly, 
the rmsd between C’s 14B7* and M18 is 0.54 Å.  The only significant difference occurs 
in the CDR H3 loop of M18 with a C rmsd of 2.0 Å.   
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However in the PAD4-M18 complex, the H3 loop assumes a conformation more 
like that of 14B7* and 1H.  In the 14B7* and 1H scFv crystals, the H3 loop packing 
involves hydrophobic contacts between heavy chain L101 and L102 interacting between 
two adjacent molecules related by crystallographic symmetry.  This differs from the 
packing in the P1 crystal of M18 scFv, where L101 makes hydrophobic contacts with 
heavy chain W33 and Y52, as well as light chain T93 and a leader Lys in an adjacent 
molecule.  L102 is contacted by light chain P95 and heavy chain F47 in an adjacent 
molecule.  Although the difference in H3 conformation appears to be due to crystal 
packing forces, it does demonstrate the flexibility of the H3 loop.  A superposition of the 
C traces of the 14B7*, 1H, and M18 scFv’s, along with that of M18 from the antibody-
antigen complex C traces is shown in Figure 2.3. 
Analysis of the temperature factors associated with the CDR H3 relative to the 
temperature factors of the remaining heavy chain reveals an increase that is statistically 
significant for CDR H3 in 1H and M18 (Table 2.2).  This implies that there is increased 
flexibility in the CDR H3 loop compared to other regions in the scFv molecule. 
 
Table 2.2.  B-factor analysis of 14B7, 1H, and M18. 
Crystal Structure Light Chain Heavy Chain - CDR H3 CDR H3 P-value*
14B7 11 ± 3 12 ± 3 12 ± 3 0.22
1H 13 ± 5 14 ± 6 16 ± 5 0.00016
M18 16 ± 6 16 ± 5 23 ± 5 7.0 x 10-19
* Two-tailed t-test assuming unequal variances between CDR H3 and Heavy Chain - CDR H3
Mean B-factor
 
2.3.3 PAD4 structure 
The structure of the Anthrax Protective Antigen (PA83 or, simply PA) has been 
solved previously at high resolution, both as the apo-protein (Petosa et al. 1997) and in 
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complex with the Anthrax toxin receptor (Santelli et al. 2004).  The majority of contacts 
between PA83 and the CMG2 cellular receptor are made with PA domain 4 (PAD4), 
although some contacts with PA domain 2 are also seen.  PAD4 consists of an initial β-
hairpin and α-helix, followed by an immunoglobulin-like -sandwich composed of two 4-
stranded antiparallel β-sheets.  Residues 592-735 are observed for the four PAD4 
monomers in the asymmetric unit of the PAD4-M18 crystal.  A cartoon and surface  
 
FIGURE 2.3 - SUPERPOSITION OF BACKBONE TRACES OF UNBOUND SCFV 
14B7*, 1H, AND M18 ALONG WITH M18 FROM THE ANTIGEN-ANTIBODY COMPLEX.  
The trace of 14B7* is shown in dark blue, 1H in light blue, unbound M18 in red, and 
M18 from the complex in cyan.  CDR loops from the bound M18 are shown thicker in 
yellow.   
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drawings of the PAD4-M18 complex are shown in Figures 2.4a and 2.4b.  The 
PAD4 domain complexed with antibody is virtually identical to that from the unbound 
antigen (C rmsd of 0.7 Å), indicating that antibody binding does not cause significant 
conformational change in the antigen.  A superposition of the C traces of the unbound 
and antibody-bound PAD4 is shown in Figure 2.4c.  
A B C
 
FIGURE 2.4 – REPRESENTATIONS OF THE PAD4-M18 COMPLEX.  (a) Ribbon drawing 
of the PAD4-M18 complex.  PAD4 is shown in blue, the M18 light chain in cyan, and the 
M18 heavy chain in magenta.  The M18 CDR loops are shown in yellow; the PAD4 cell 
receptor binding loops are shown in red.   (b) Surface view of PAD4-M18 structure with 
the same colors and orientation as (a).  (c) Superposition of backbone traces of unbound 
PAD4 (Petosa et al. 1997) and PAD4 from the PAD4-M18 complex.  PAD4 from the 
M18 complex is shown in cyan and unbound PAD4 in blue.  The receptor binding loops 
are shown in red. 
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2.3.4 Antigen-antibody interface 
The PAD4-M18 complex has a buried surface area of ~1700 Å2.  As expected, the 
CDRs of both the light and heavy chains of M18 face PAD4 in the antibody-antigen 
complex.  All of the CDRs except L3 make some direct contact with PAD4, but the 
strongest interactions are made with H3 and L2.  The major epitope of PAD4 is at an end 
of one of its β sheets (strands 5-6-9-10).  There are three main contact loops: (1)  5-6 
(residues 646-658), comprised of the loop between strands 5 and 6, strand 6, and the loop 
immediately following strand 6; (2) 3-9 (residues 683-694), the loop between helix 3 
and strand 9; (3) pre-10 (residues 716-719), the loop immediately preceding strand 10.   
The M18 complex interface centers on PAD4 residues Y688 and L685.  Y688 
forms hydrophobic interactions with L2 residue Y49 and H3 residues L101 and L102, as 
shown in Figure 2.5a.  L685 is a surface leucine, which upon binding with M18, is 
inserted into a pocket formed by CDRs H1 and H3 and the side chains of heavy chain 
residues W33 and L101.  An additional hydrophobic interaction is formed between L652 
and light chain residue Y50, and P686 also makes hydrophobic contact with heavy chain 
residue L101. 
The complex is further stabilized by hydrophilic interactions, many of which are 
shown in Figure 2.5b.  The hydroxyl of Y688 forms a hydrogen bond with the OE1 atom 
of L2 residue Q55.  Several ion pairs are formed between PAD4 loops and CDRs L1, L2, 
and H2.  These include D658 with L1 residue R30, D648 with L2 residue R53, D683 
with H2 residue R50, and K684 with H2 residue D57.  Several more hydrogen bonds are 
formed between all three PAD4 loops and CDR loops L1, L2, H1, and H3. 
 Previously, alanine-scanning experiments with residues 657 and 679-693 of 
PAD4 implicated N682, K684, L685, P686, L687, and Y688 as being significant for 
interactions with 14B7 (Rosovitz et al. 2003) (Figure 2.5c).  By far, the largest effect on 
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14B7-binding was found for the L685A substitution, which showed a 10,000-fold 
decrease in binding affinity.  It was also found that substitutions for N682, L687, and 
Y688 each reduced binding to 14B7 ~100-fold, while substitutions for K684 and P686 




FIGURE 2.5 – THE PAD4-M18 INTERFACE.  In these four panels, the M18 CDR 
loops are shown in yellow and labeled, and the PAD4 binding loops are shown in red.  (a) 
Residues involved in specific hydrophobic interactions at the interface are shown.  (b) 
Residues involved in hydrophilic interactions are shown.  Hydrogen bonds are shown 
with a dashed line.  (c) PAD4 residues indicated by alanine-scanning experiments to 
contribute to the binding of 14B7 (Rosovitz et al. 2003) are shown along with M18 
residues observed to participate in hydrophobic interactions at the PAD4-M18 interface.  
(d) M18 residues indicated by alanine-scanning experiments to contribute to the binding 
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of PAD4 (Sivasubramanian et al. 2008) are shown with hydrophobic PAD4 residues 
observed to interact with M18.  D683, known to interact with the MIDAS metal, is also 
shown.   
 
In light of the PAD4-M18 structure, it is easy to rationalize the results found with 
PAD4 substitutions like K684A, L685A, P686A, and Y688A, each of which show clear 
interactions with M18 and significant buried surface area.  Rationalizations for the 
reduced binding to 14B7 by the L687A and N682A variants are less obvious.  L687 does 
not interact directly with the antibody, but may act as a key second shell residue, 
affecting the folding of PAD4 and the conformation of the epitope.  L687 does form 
hydrophobic interactions with other PAD4 residues such as I646, I656, F678, and V696.  
N682 does not form any favorable interactions with PAD4 in the complex, but is pointed 
toward the backbone of heavy chain residues 101 and 102.    
Previous results with alanine substitutions on the 14B7 structure are similarly 
easy to rationalize in large part (Sivasubramanian et al. 2008).  Light chain residues Y50 
and R53, as well as heavy chain residues W33, R50, Y52, and Y104 were found to be 
very important for binding, and these are all on the binding interface with PA (Figure 
2.5d).  Light chain residues W35, N92, and W96 were also found to be important in the 
alanine scan, but each of these are located within the interior of the light chain fold so 
they are likely key to establishing a stably folded structure.   
 
2.3.5 Comparison to PAD4-CMG2 receptor interface 
Previously, the structure of the complex of PA with the I domain of its host cell 
receptor, CMG2, was solved at 2.5 Å resolution (Santelli et al. 2004).  There is a buried 
surface area of 1920 Å2 in the PA-CMG2 receptor complex, of which ~1360 Å2 is buried 
 63 
by the PAD4-receptor interface. The remainder is buried by the interface of the receptor 
with PA domain 2.  There is no evidence that the 14B7 family of antibodies, including 
M18, contacts PA outside of domain 4.  A superposition of the entire PA molecule (with 
domain 4 superimposed on that of our complex) indicates that M18 would contact only 
domain 4.  That is, our complex represents the complete interaction of M18 with the PA 
protein. 
Overall, the binding interfaces found in the PAD4-CMG2 and PAD4-M18 
structures overlap well (Figure 2.6a).  The CMG2 receptor interacts with the same three 
binding loops of PAD4 observed to make antibody contacts in the PAD4-M18 complex, 
and several of the PA residues are important in both cases (L682, P686, L687) based on 
alanine scanning results (Rosovitz et al. 2003).  The binding interface between PAD4 and 
the CMG2 centers on a key interaction between D683 of PAD4 and a Mg atom bound in 
a so-called MIDAS (metal ion dependent adhesion site) motif of CMG2.  In this way, the 
PA is mimicking the ligand recognition of integrins.  Not surprisingly, when D683 is 
replaced by Ala, all PA toxicity is lost, presumably because the D683A variant cannot 
bind the CMG2 or other cellular receptors such as TEM8 (Rosovitz et al. 2003).  
However, when D683 was converted to alanine, there was no measurable affect 
on the PAD4-14B7 interaction (Rosovitz et al. 2003).  In the PAD4-M18 structure, D683 
is found in the middle of the protein-protein interface, and makes a salt bridge with H2 
residue R50 of M18 (Figure 2.5b).  It is unclear why the loss of this ionic interaction 
should have so little effect on PAD4 antibody interaction.  It is possible that a new 
hydrophobic contact is created in the D683A variant that adventitiously balances any 
binding energy lost with the elimination of the D683-R50 salt bridge. 
There are some other clear differences between the PAD4-CMG2 and PAD4-M18 
structural interactions.  For example, the PAD4-CMG2 binding interface shows the 
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insertion of the CMG2 V115 side chain into a pronounced hydrophobic “socket” in 
PAD4 composed of I646, I656, and L687 (Figure 2.6b).  In contrast, in the PAD4-M18 
complex, this same PAD4 hydrophobic socket is not occupied by any antibody residue, 
hydrophobic or otherwise.   
A B
 
FIGURE 2.6 – PAD4-CMG2 COMPLEX IN RELATION TO THE PAD4-M18 
COMPLEX.  (a) Superposition of the PAD4-CMG2 receptor complex with the PAD4-
M18 complex.  PAD4 is shown in blue, the CMG2 receptor in green, and M18 in 
magenta.  The receptor binding loops are shown in red.  (b) PAD4-CMG2 receptor 
interface.  Residues involved in specific interactions at the interface are shown, including 
the interaction of D683 with the MIDAS metal ion and the “hydrophobic socket”.  The 
PAD4 binding loops are shown in red, and the CMG2 receptor is in yellow.  Coordinates 
were taken from the PAD4-CMG2 receptor complex (Santelli et al. 2004). 
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2.3.6 Structural aspects of 14B7 affinity maturation  
In an effort to create a therapeutic anti-toxin antibody for use as a prophylactic as 
well as late stage treatment for anthrax, 14B7 was used as the platform for an antibody 
engineering effort.  Initially, sequence randomization followed by phage display was 
used to affinity mature 14B7, resulting in 1H (250 pM) (Maynard et al. 2002).  This 
approximately 20-fold affinity enhancement means that 1H has a higher affinity for PA 
than do the cellular receptors.  Presumably for this reason, a humanized, whole IgG form 
of 1H, now called AnthimTM, was shown to be an effective prophylactic and post-
infection treatment for inhalation anthrax in animal models.  AnthimTM successfully 
completed a phase I clinical human safety trial and is currently in later stages of 
development.  
The two key changes in 1H relative to 14B7 are light chain residues Q55L and 
S56P.  Both changes increase hydrophobicity on the periphery of the binding interface 
with PA and, by analogy to the PAD4-M18 structure, will contact Y688 and S690 of PA.  
For example, the Cδ atom of P56 contacts Cα and Cβ of S690.   It is tempting to ascribe 
the affinity enhancement to an increase in hydrophobic contacts.    
The ultrahigh affinity variant M18 shares the S56P mutation with 1H and 
presumably makes similar interactions with the antigen.  However, M18 does not contain 
the Q55L mutation.  In the PAD4-M18 structure, only the polar –OH group of Y688 
makes contact with the 55 and 56 side chains.  In fact, in the case of Q55 of M18, there is 
a predicted hydrogen bond that will be lost upon replacement with leucine in 1H.  
Comparison of the 14B7 backbone conformation to that of 1H (and M18) in this region 
reveals no significant change in folded structure (Figure 2.3).  Because the PAD4-M18 
structure does not have the Q55L mutation, we can only speculate that there is some 
contribution from a hydrophobic contact with Y688 by L55 in 1H.  Finally, considering 
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the constrained conformational dynamics of a proline moiety, it is worth considering that 
a major contribution of the S56P and possibly Q55L mutations could be to alter the 
dynamics of the L2 loop to be more favorable for binding. 
Besides S56P, only the L46F mutation in M18 is located near the binding 
interface with PA (Figure 2.7).  The role of L46 in affinity enhancement is not obvious, 
but may include a slight hydrophobic contact with Y688 of PA.  The F46 C2-Y688 C2 
distance is 5.3 Å.  F46 forms a stronger hydrophobic interaction with the side chain of 
L102 in the H3 loop; L102, in turn, is within 4 Å of the Y688 side chain so L46 may be 
acting to stabilize, indirectly, an important hydrophobic contact.  In addition, the 
proximity of L46F to S56P might mean that they are working in concert to control subtle 
features of the conformation or dynamics of the L2 loop.  Of course, we should not rule 
out the possibility that some of the other mutations in M18 contribute to an increase in 
affinity through subtle, indirect effects. 
A B
 
FIGURE 2.7 - AFFINITY MATURATION MUTATIONS OF M18 AND 1H.  (a) The 
M18 light chain is shown in cyan, and the M18 heavy chain in magenta.  The side chains 
of M18 variant residues are shown in black.  The M18 CDR loops are shown in green and 
labeled.  PAD4 is shown in black, and the PAD4 binding loops are shown in red.  (b) The 
PAD4-binding face of M18 is shown.  Mutations of M18 are shown in red.  The Q55L 
mutation of 1H is shown in green. 
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Interestingly, the contributions of L46F, Q55L, and S56P appear to be additive 
based on a preliminary analysis.  For example, adding the Q55L mutation to M18 (which 
already contains L46F and S56P) leads to a new variant called M18.1 that exhibits a 
dissociation constant of 21 pM, representing the highest affinity observed to date in the 
14B7 family of engineered antibodies (Table 2.3).  Unfortunately, this enhanced affinity 
comes at the expense of expression level as M18.1 expresses significantly more poorly 
than M18 in E. coli.  Adding L46F to 14B7 enhances binding affinity by an order of 
magnitude, and removing L46F from M18 causes an analogous decrease in affinity   
(Table 2.3). 
 
Table 2.3.  Kinetic data for selected 14B7 and M18 variants 
Clone koff (1/s, x10
-5
) kon (1/Ms, x10
6
) KD (pM)
14B7 390 ± 40 1.5 ± 0.3 2500 ± 600
14B7-L46F 40. ± 4 1 ± 1 300 ± 300
M18-F46L 32 ± 4 0.6 ± 0.4 500 ± 400
M18 5 ± 2 1.0 ± 0.6 50 ± 30  
2.4 CONCLUSIONS 
Overall the PAD4-M18 crystal structure can be used to nicely rationalize the 
extensive alanine scanning mutagenesis data available for this system.  The one exception 
is the PA D683 position that would appear to make an important contribution to M18 
binding, even though this is not reflected in the previously reported D683A variant of PA 
binding to 14B7.  In addition, the results of affinity enhancements obtained by either 
phage panning (1H) or APEx (M18) can be rationalized as changes in key interactions in 
this same region of the interface, contacting Y688 and/or S690 of PA.  However, a 
detailed explanation for the energetic contributions from other mutations  in M18 known 
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to contribute to affinity enhancement, for example L46F, is not straightforward although 
it does appear to be operating in an additive fashion. 
The PAD4-M18 structure can serve as the basis for engineering a new generation 
of ultrahigh affinity anti-PA antibodies.  For example, using targeted mutagenesis, it may 
be possible to fill the hydrophobic “socket” in PAD4 composed of I646, I656, and L687 
and thereby enhance the already very strong PA-antibody interaction.  In addition, if a 
variant of PA is derived either from natural or deliberate variation, the PAD4-M18 
structure will serve as an invaluable reference for designing targeted libraries that should 
be able to yield a high affinity therapeutic derivative of 14B7 in a timely fashion. 
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Bacillus anthracis is the gram-positive, spore forming bacterium that is the 
causative agent of the zoonotic disease, anthrax (Moayeri and Leppla 2004; Young and 
Collier 2007).  Unfortunately, because of its robust spore, ease of production, and 
associated fatality when inhaled or eaten, this disease has long been feared as a 
potentially very effective bioweapon.  The inadvertent release of spores from Sverdlosk 
in 1979, and the resulting 77 human deaths, revealed how efficient B. anthracis can be as 
a bioweapon (Meselson et al. 1994), and the Anthrax letter attacks of 2001 serve to 
illustrate the fear, confusion, and chaos that can be created by such an asymmetric threat. 
The current anthrax vaccine has significant side effects that make it unlikely to be 
used to vaccinate the entire American public, and there is a large amount of research 
being carried out to create a new, safer vaccine.  Because there is a gap in coverage, and 
thus the opportunity for a similar or worse outcome than in 2001, our laboratory and 
others have worked to produce therapeutics that can treat anthrax (Little et al. 1988; 
Cirino et al. 1999; Sellman et al. 2001; Kobiler et al. 2002; Maynard et al. 2002; Wild et 
al. 2003; Brossier et al. 2004; Harvey et al. 2004; Sawada-Hirai et al. 2004; Turk et al. 
2004; Mabry et al. 2005; Mohamed et al. 2005; Shoop et al. 2005; Subramanian et al. 
2005; Chen et al. 2006; Jiao et al. 2006; Peterson et al. 2006; Rivera et al. 2006; Vitale et 
al. 2006; Albrecht et al. 2007; Pelat et al. 2007; Steiniger et al. 2007).  Several of these 
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therapies have even been shown to be very effective in animal models (Little et al. 1997; 
Karginov et al. 2004; Cui et al. 2005; Vitale et al. 2006; Kelly et al. 2007). 
However, what is not well understood is whether these therapeutics would be 
useful in the face of natural or deliberate variation of the anthrax toxin genes.  In fact, 
alanine scanning of the protective antigen revealed several mutations that prevented the 
14B7 family of antibodies from binding and neutralizing the toxin, and some of these 
variants still retained their toxic activity (Rosovitz et al. 2003).  This underlines the 
importance of, first, uncovering the method and mechanism of interaction of these 
various therapeutics with the toxin; second, understanding the limitations of these 
therapeutics based upon these molecular constraints; and third, developing a second 
generation of therapeutics that can counter any perceived threats. 
The ideal antibody countermeasure to anthrax would provide a general solution 
even against altered toxins.  With this in mind, our approach was to utilize the 
crystallographic characterization of the interaction of first-generation anthrax therapeutics 
to enable the development of potential second generation countermeasures.  As a starting 
point, our laboratory had previously undertaken to evolve an antibody fragment from the 
14B7 family of antibodies that could bind to PA-Y688A, a point mutant of PA that 
greatly reduced binding affinity of 14B7 (>100-fold) while retaining its toxic activity.  In 
the absence of the crystallographic model of interaction, all attempts had failed to 
develop a 14B7 variant with enhanced affinity to PA-Y688A.  Error-prone libraries and 
very large saturation mutagenesis libraries did not yield affinity-improved binders (Jeong, 
K.J., unpublished data).  Our new effort, which turned out to be successful, used key 
information from the structure of the M18-PAD4 interaction to create focused libraries 
that allowed for the isolation of variants with enhanced affinity for PAD4-Y688A. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 PAD4 Construction 
PAD4 was cloned into pET17b under the control of a T7 promoter with an N-
terminal 3xFlag tag and a C-terminal 6xHis tag between the NdeI and BamHI sites.  PCR 
was performed on the PAD4 gene to introduce these features utilizing the following 
primers: forward  
GGCGGCGGCCATATGGATTATAAAGATCATGATGGCGATTATAAAGATCATG
ATATTGATTATAAAGATGATGATGATAAATTCCACTACGATCGTAACAATATC
GCGG, and reverse  
GGCGGCGGCGGATCCTTATTAGTGATGGTGATGATGATGACCAATTTCATAG
CCCTTTTTGCTAAAAATCAGG.   
PAD4-Y688A was constructed using site-directed mutagenesis via overlap PCR.  
First, two PCR reactions were carried out to synthesize two fragments of the gene of 
interest with the internal primers containing the codon changing residue 688 from 
tyrosine to alanine  (Outer primers--Fragment 1 forward primer: 
TAATACGACTCACTATAGGG, Fragment 2 reverse primer: 
GCTAGTTATTGCTCAGCGG; Inner primers-- Fragment 1 reverse primer: 
CGTTCACTTCGTAGTTTGGATTGCTGATCGCCAGCGGCAATTTGTCGTTGTAC, 
Fragment 2 forward primer: GCGATCAGCAATCCAAACTACGAAGTGAACG).  
These two PCR fragments were purified by agarose gel electrophoresis, and mixed 
together as template for a second PCR reaction to yield the full-length gene fragment.  
Only the outer primers were used for amplification of this second reaction.  Digestion of 
this fragment was accomplished with NdeI and BamHI and subjected to agarose gel 
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electrophoresis, which was then ligated with pET17b vector that had been cleaved with 
NdeI and BamHI.  Ligations were desalted using Millipore desalting membrane for 1 hr.  
Reactions were subsequently transformed via electroporation into Jude-1 cells and plated 
on LB-Agar with 2% glucose and Ampicillin at 100 µg/mL and grown overnight at 37°C.  
Individual colonies were picked and grown overnight in liquid culture of LB with 2% 
glucose and Ampicillin at 100 µg/mL at 37°C.  Plasmid was isolated from each culture 
by Miniprep (Qiagen), and sequencing was performed on individual clones by the ICMB 
Sequencing Core Facility. 
After the correct sequence was determined for each construct, plasmid was 
transformed by electroporation into KRX cells (Promega), which were plated on LB-
Agar with 2% glucose and Ampicillin at 100 µg/mL and grown overnight at 37°C.   
Individual colonies were picked and grown overnight in liquid culture of LB with 2% 
glucose and Ampicillin at 100 µg/mL at 37°C.  Frozen stocks were made by mixing 
liquid culture with 50% glycerol 2:1, for a final glycerol concentration of 16%; cells were 
frozen at -80°C.   
 
3.2.2 PAD4 Expression and Purification 
 Overnight cultures 40 mL in volume of TB with 2% glucose and Ampicillin at 
100 µg/mL were inoculated from frozen stocks and incubated at 37°C.  The next day, this 
culture was used to inoculate 1 L of TB with Ampicillin at 100 µg/mL, which was 
incubated at 37°C for 4 hours, then 1 g of L-rhamnose (Sigma) was added to each liter of 
culture and induction was allowed to continue overnight.  The following morning, cells 
were pelleted and resuspended in 50 mL of 50 mM Tris, pH 8.0, 500 mM NaCl, 10 mM 
imidazole.  Cells were lysed by sonication (Probe dismembrator, Fisher Scientific) on ice 
in 5 mL aliquots by 3 cycles of 30 s at level 5 followed by 30 s off.  Membranes were 
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pelleted by centrifugation at 8,000 rpm for 20 minutes.  Supernatant was equilibrated 
with 1 mL Ni-NTA Agarose (Qiagen) per liter of culture that had been washed three 
times in binding buffer.  The cell lysate-bead mixture was mixed on ice for one hour.  
The Ni-NTA agarose beads were washed twice in batch by centrifugation at 3,000 rpm 
for 5 minutes, decanting of supernatant, followed by resuspension in 50 mM Tris, pH 8.0, 
500 mM NaCl, 20 mM imidazole.  The washed beads were then placed in a disposable 
polypropylene column (Pierce), and protein was eluted by addition of 4- 1 mL fractions 
of 50 mM Tris, pH 8.0, 500 mM NaCl, 250 mM imidazole.  The eluent was dialyzed and 
concentrated into 50 mM Tris, pH 8.0, 150 mM NaCl buffer using an Amicon Ultra 15, 
10,000 MWCO filter.  Protein concentrations were assessed using the BCA assay (Pierce) 
with BSA as a control. 
 
3.2.3 M18-NNS Library Construction 
Overlap PCR, as described above, was used to construct both the NNS3 and 
NNS8 libraries.  As there were two locations in the primary sequence where diversity 
was to be introduced, three segments were amplified initially (NNS3/NNS8 Outside 
primers—Fragment 1 forward primer: CGGATAACAATTTCACACAGG, Fragment 3 
reverse primer: CGCAGTAGCGGTAAACGGC; NNS3 Internal primers--Fragment 1 
reverse primer: 
TAATCTTGATGTGTAGTAGATCAGGAATTTAACAGTTCCGTCTGG, Fragment 2 
forward primer:  
CCAGACGGAACTGTTAAATTCCTGATCTACTACACATCAAGATTANNSNNSGG
AGTCCCATCAAGGTTCAGTGGC, Fragment 2 reverse primer: 
CCCCGATCTTGCACAGAAATAGACCG, Fragment 3 forward primer: 
CGGTCTATTTCTGTGCAAGATCGGGGNNSCTACGTTATGCTATGGACTACTGG
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GGTCAAGG; NNS8 Internal primers—Fragment 1 reverse primer: 
TTTAACAGTTCCGTCTGGTTTCTGCTGATACC, Fragment 2 forward primer: 
GGTATCAGCAGAAACCAGACGGAACTGTTAAANNSCTGATCNNSTACACATC
ANNSTTANNSNNSGGAGTCCCATCAAGGTTCAGTGGC, Fragment 2 reverse 
primer: CCCCGATCTTGCACAGAAATAGACCG, Fragment 3 forward primer: 
CGGTCTATTTCTGTGCAAGATCGGGGNNSNNSCGTTATGCTATGNNSTACTGG
GGTCAAGGAACCTCAGTCACC).  After agarose gel electrophoresis, the purified 
fragments were mixed and amplified with only the outside forward primer from fragment 
1, and the outside reverse primer from fragment 3.  After purification by PCR cleanup 
(Zymo Research), the PCR fragment was digested with SfiI.  Agarose gel electrophoresis 
was used to purify the restricted fragment, and the insert was ligated into previously SfiI-
digested pAPEx1 plasmid for 4 hours at room temperature.  After desalting for one hour, 
MC1061 cells were transformed with the desalted ligation reaction via electroporation 
and grown for one hour in SOC media with 2% glucose at 37°C.  These cells were then 
plated on TB-Agar with 2% glucose and chloramphenicol at 30 µg/mL and grown 
overnight at 30°C before being scraped and frozen away at -80°C in TB media with 16% 
glycerol. 
 
3.2.4 Library Sorting 
Screening of libraries was carried out using the APEx protocol (Harvey et al. 
2004).  Overnight cultures or frozen cells were used to seed 40 mL of TB with 2% 
glucose and 40µg/mL chloramphenicol at an OD600 of 0.2.  Cultures were grown at 37°C 
for 4 hours, centrifuged for 6 minutes at 3,500 rpm, and resuspended in 40 mL of TB 
with 1 mM IPTG and 40µg/mL chloramphenicol.  Induced cultures were shaken at 25°C 
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for 4 hours.  An equivalent volume of cells to 1 mL at OD600 of 3.0 was taken for 
spheroplasting and labeling.   
Spheroplasting was accomplished by resuspending cells in 350 µL of 100 mM 
Tris, pH 7.5, 750 mM sucrose, mixing with 700 µL 1 mM EDTA and 40 µL of 20 
mg/mL hen egg lysozyme and mixing for 20 minutes at room temperature.  50 µL of 0.5 
M MgCl2 was added and the cell suspension was placed on ice for 10 minutes.  
Spheroplasts were centrifuged for 6 minutes at 10,000 rpm and resuspended in 500µL 
1xPBS with 2% BSA.  125µL of spheroplasts were subjected to various labeling 
concentrations of either wild-type PAD4 or PAD4-Y688A, and allowed to shake in the 
dark for one hour at room temperature.  Spheroplasts were then pelleted again at 10,000 
rpm for 6 minutes, resuspended in 100 µL of 20 µg/mL anti-Flag-PE, and shaken in the 
dark for one hour at room temperature. 
Labeled samples were then diluted into 1xPBS with 2% BSA and sorted on a 
MoFlo (Dako) fluorescence activated cell sorter using the 488 nm Argon laser line for 
excitation, and a 570/40 nm bandpass filter to observe emission of PE.  Spheroplasts were 
sorted at a rate of 30,000 events per second, and approximately the top 2% most 
fluorescent of gated spheroplasts were collected.  Collected spheroplasts were subjected 
to an immediate re-sort utilizing the same gates as the initial sort. 
Colony PCR was carried out on re-sorted spheroplasts to amplify the scFv genes 
(forward primer: CGGATAACAATTTCACACAGG, reverse primer: 
CGCAGTAGCGGTAAACGGC).  After purification using a PCR cleanup kit (Zymo 
Research), the PCR fragments were digested with SfiI, purified by agarose gel 
electrophoresis, and ligated into pAPEx1 previously excised with SfiI.  After desalting 
for one hour, MC1061 cells were transformed with the desalted ligation reaction via 
electroporation and grown for one hour in SOC media with 2% glucose at 37° C.  These 
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cells were then plated on TB-Agar with 2% glucose and chloramphenicol at 30 µg/mL 
and grown overnight at 30°C before being scraped and frozen away at -80°C in TB media 
with 16% glycerol.  Aliquots of the library were prepared such that thawing and dilution 
into 40 mL of media would yield a cell suspension at an OD600 of 0.2.  Frozen stocks of a 
round of sorting were used to inoculate subsequent cultures for additional rounds of 
sorting. 
  
3.2.5 SINGLE WELL ELISA SCREENING 
 Initial ELISA screening was performed essentially as described by Mazor, et al 
(Nature Protocols, submitted).  After four rounds of sorting, colony PCR was carried out 
on re-sorted spheroplasts to amplify the scFv genes (forward primer: 
CGGATAACAATTTCACACAGG, reverse primer: CGCAGTAGCGGTAAACGGC).  
After purification using a PCR cleanup kit (Zymo Research), the PCR fragments were 
digested with SfiI, purified by agarose gel electrophoresis, and ligated into pMoPac16 
previously excised with SfiI.  After desalting for one hour, MC1061 cells were 
transformed with the desalted ligation reaction via electroporation and plated on TB-Agar 
with 2% glucose and Ampicillin at 100 µg/mL and grown overnight at 30°C.  Individual 
colonies were picked and used to inoculate 200 µL of LB media with 2% glucose and 
100 µg/mL Ampicillin in 96 well plates, which were shaken at 30°C overnight.  The next 
day, this master plate was wrapped in parafilm and stored at 4°C.  10 µL from each 
master plate was used to inoculate 190 µL of TB media with 2% glucose and 100 µg/mL 
Ampicillin, which was shaken at 30°C for 3 hours.  Plates were then centrifuged at 4450 
rpm for 15 minutes, supernatant was decanted, cells were resuspended in 200 µL of TB 
induction media with 1 mM IPTG and 100 µg/mL Ampicillin, and left to shake overnight 
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at room temperature.  ELISA plates were then coated overnight at 4°C with 50 µL of 3 
µg/mL PAD4-Y688A in PBS or 3 µg/mL human transferrin in PBS as a negative control. 
After coating overnight, the ELISA plates were washed with PBS with 0.05% 
Tween-20 using a SkanWasher 300 (Molecular Devices); all subsequent washing was 
carried out using this instrument.  ELISA plates were then blocked for 4 hours at room 
temperature in 2% milk in PBS.  Cell plates that had incubated at room temperature 
overnight were centrifuged at 4450 rpm for 15 minutes, supernatant was decanted, cells 
were resuspended in 200 µL of 20% Bugbuster-HT in PBS, and shaken at room 
temperature for 1 hour.  Cell debris was pelleted by centrifugation at 4450 rpm for 15 
minutes, and 10 µL of scAb-containing supernatant was added to 90 µL of 2% milk in 
PBS.  ELISA plates were then washed with PBS with 0.05% Tween-20.  100 µL of 
supernatant diluted in milk-PBS was applied to a well coated in PAD4-Y688A as well as 
one coated with human transferrin, and allowed to incubate at room temperature for 1 
hour.  ELISA plates were washed with PBS with 0.05% Tween-20, and then incubated 
with a 1:2500 dilution of anti-Human Kappa chain IgG-HRP in PBS with 2% milk for 1 
hour at room temperature.  ELISA plates were then washed with PBS with 0.05% Tween-
20 and developed with 100 µL of TMB substrate.  Development was quenched by adding 
100 µL of 4.5 M H2SO4, mixing gently, and then was read at 450 nm using a 96-well 
plate reader.  
 
3.2.6 scAb Expression and Purification for Plate ELISA Screening 
Cultures 4 mL in volume of TB media with 2% glucose and 100 µg/mL 
Ampicillin were inoculated using 20 µL of selected clones from the master plate made 
during single well ELISA screening, and placed on a shaker at 37°C overnight.  In the 
morning, the 4 mL culture was poured into 40 mL of TB media with 2% glucose and 100 
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µg/mL of Ampicillin and placed on a shaker at 37°C for 4 hours.  The culture was 
centrifuged at 4500 rpm for 6 minutes, supernatant was decanted, cells were resuspended 
in 40 mL of TB media with 1 mM IPTG and 100 µg/mL of Ampicillin and placed on a 
shaker at room temperature for 4 hours.  Cultures were then centrifuged at 4000 rpm for 
15 minutes, supernatant was decanted, and cells were resuspended in 1 mL of 100 mM 
Tris, pH 7.5, 750 mM sucrose.  Cells were mixed by swirling on ice while 2 mL of 1 mM 
EDTA was added dropwise, followed by addition of 0.1 mL of 10 mg/mL hen egg 
lysozyme.  Cells were left to mix by swirling on ice for 30 minutes.  Next, 140 µL of 0.5 
M MgCl2 was added to stabilize spheroplasts and chelate free EDTA, and the mixture 
was allowed to swirl on ice for 10 minutes.  Spheroplasts were pelleted by centrifugation 
at 6000 rpm for 25 minutes; the scAb-containing supernatant was decanted into a new 
tube, 350 µL of 10x IMAC buffer (0.2 M Tris, pH 8.0, 5M NaCl, 0.1M imidazole, 1% 
Tween-20) was added and gently mixed,  and then equilibrated with 0.5 mL Ni-NTA 
agarose beads washed 3 times with 1x IMAC buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 
10 mM imidazole, 0.1% Tween-20).  The agarose beads were allowed to incubate on ice 
while shaking with the supernatant for one hour, and then they were pelleted at 3000 rpm 
for 5 minutes in a swinging bucket centrifuge.  Beads were washed twice by addition of 
50 mL of ice-cold 1x IMAC buffer, centrifugation at 3000 rpm for 5 minutes, and gentle 
decanting of the supernatant.  Beads were placed in a 5 mL disposable polypropylene 
column (Pierce) and scAb was collected in four subsequent elutions of 1 mL each of 50 
mM Tris, pH 8.0, 500 mM NaCl, and 250 mM imidazole.  The eluent was dialyzed and 
concentrated into 50 mM Tris, pH 8.0, 150 mM NaCl buffer using an Amicon Ultra 15, 
10,000 MWCO filter.  Samples were then filtered using 0.22 µm Ultrafree-MC basket 
filters with PVDF membranes (Millipore).  Protein concentrations were assessed using 
the BCA assay (Pierce) with BSA as a control; purity was assessed by PAGE. 
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3.2.7 Plate ELISA Screening 
ELISA plate wells were coated with 100 µL of 3 µg/mL PAD4-Y688A in PBS 
overnight at 4°C.  The following morning, the plates were washed with 1x PBS with 
0.05% Tween-20 using a SkanWasher 300 and then allowed to block for 4 hours at room 
temperature with 2% milk in PBS.  scAb’s were diluted to 1 µM in 2% milk-PBS, loaded 
on to the plate, and subjected to 1:1 serial dilutions with 2% milk-PBS across the 
remaining 11 rows of the plate; 100 µL was left in each well.  This was incubated at room 
temperature for one hour before washing with 0.05% Tween-20 in PBS.  100 µL of anti-
Human Kappa chain IgG-HRP conjugate diluted 1:2500 into 2% milk-PBS was applied 
to each well and allowed to incubate at room temperature for 1 hour.  ELISA plates were 
then washed with PBS with 0.05% Tween-20 and developed with 100 µL of TMB 
substrate.  Development was quenched by adding 100 µL of 4.5 M H2SO4, mixing gently, 
and then was read at 450 nm using a 96-well plate reader. 
 
3.2.8 Expression and Purification of scAb’s for Kinetic Studies 
Cultures 40 mL in volume of TB media with 2% glucose and 100 µg/mL 
Ampicillin were inoculated using 20 µL of selected clones from the master plate made 
during single well ELISA screening, and placed on a shaker at 37°C overnight.  In the 
morning, the 40 mL culture was poured into 400 mL of TB media with 100 µg/mL of 
Ampicillin and placed on a shaker at 37°C for 4 hours.  The culture was induced by 
addition of IPTG to 1 mM and placed on a shaker at room temperature for 4 hours.  
Cultures were then centrifuged at 7000 rpm for 10 minutes, supernatant was decanted, 
and cells were resuspended in 10 mL of 100 mM Tris, pH 7.5, 750 mM sucrose.  Cells 
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were mixed by swirling on ice while 20 mL of 1 mM EDTA was added dropwise, 
followed by addition of 1 mL of 10 mg/mL hen egg lysozyme.  Cells were left to mix by 
swirling on ice for 30 minutes.  Next, 1.4 mL of 0.5 M MgCl2 was added to stabilize 
spheroplasts and chelate free EDTA, and the mixture was allowed to swirl on ice for 10 
minutes.  Spheroplasts were pelleted by centrifugation at 8000 rpm for 20 minutes; the 
scAb-containing supernatant was decanted into a new tube, 3.5 mL of 10x IMAC buffer 
(0.2 M Tris, pH 8.0, 5M NaCl, 0.1M imidazole, 1% Tween-20) was added and gently 
mixed,  and then equilibrated with 0.5 mL Ni-NTA agarose beads washed 3 times with 
1x IMAC buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole, 0.1% Tween-
20).  The agarose beads were allowed to incubate on ice while shaking with the 
supernatant for one hour, and then they were pelleted at 3000 rpm for 5 minutes in a 
swinging bucket centrifuge.  Beads were washed twice by addition of 50 mL of ice-cold 
1x IMAC buffer, centrifugation at 3000 rpm for 5 minutes, and gentle decanting of the 
supernatant.  Beads were placed in a 5 mL disposable polypropylene column (Pierce) and 
scAb was collected in four subsequent elutions of 1 mL each of 50 mM Tris, pH 8.0, 500 
mM NaCl, and 250 mM imidazole.  The eluent was dialyzed and concentrated into 50 
mM Tris, pH 8.0, 150 mM NaCl buffer using an Amicon Ultra 15, 10,000 MWCO filter.  
Samples were then filtered using 0.22 µm Ultrafree-MC basket filters with PVDF 
membranes (Millipore).   
The scAb-containing eluent was then subjected to size exclusion chromatography 
on a Superdex 200 column (GE Healthcare), utilizing a fast performance liquid 
chromatography (FPLC) system (ÄKTA FPLC, GE Healthcare).  Running buffer was 1x 
HBS-P (10 mM Hepes, pH 7.4, 150 mM NaCl, 0.005% Polysorbate-20), flow rate was 
0.5 mL/min, and 0.5 mL fractions were collected.  Fractions containing monomeric scAb 
based upon the FPLC profile as monitored by the 280 nm UV detector were combined 
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and concentrated using an Amicon Ultra 15, 10,000 MWCO filter.  Samples were then 
filtered using 0.22 µm Ultrafree-MC basket filters with PVDF membranes (Millipore).  
Protein concentrations were assessed using the BCA assay (Pierce) with BSA as a 
control. 
 
3.2.9 Kinetic Analysis by Surface Plasmon Resonance 
Kinetic studies were carried out on scAb’s using a Biacore 3000 (Biacore, Inc.) 
with a CM5 sensor chip.  A mixture of 0.2 M 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS) was 
injected across the carboxymethyl-dextran surface to activate it for protein 
immobilization.  Next a 20 µg/mL protein solution in 10 mM sodium acetate buffer was 
injected across the surface so that NHS-esters could react with free amines on the surface 
of the protein to create more stable amide bonds.  Deactivation of the remaining 
unreacted NHS-esters was accomplished by injecting 1 M ethanolamine-HCl, pH 8.5.  
An equal amount of resonance units of human transferrin was immobilized as a control in 
all experiments, and it was immobilized in 10 mM sodium acetate buffer, pH 5.0.  PAD4-
Y688A was coupled using 10 mM sodium acetate buffer, pH 4.0, with a target amount of 
1000 resonance units.  750 resonance units was the targeted immobilization for both 
wild-type PA83 and PA83-Y688A in 10 mM sodium acetate buffer, pH 5.0. 
Concentration series were injected for each scAb to be analyzed; a flow rate of 
100 µL/min was utilized.  Studies performed against wild-type PA83 consisted of a 1 
minute association phase and 15 minutes of dissociation in 1x HBS-P running buffer with 
concentration series of 5-20 nM for M18 and 10-40 nM for variants.  Studies carried out 
with PA83-Y688A utilized a 1 minute association and 3.5 minutes of dissociation in 1x 
HBS-P running buffer, with concentration series of 20-80 nM for M18 and 10-40 nM for 
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variants.  Studies performed on PAD4-Y688A employed a 1 minute association phase 
and 3.5 minutes of dissociation in 1x HBS-EP running buffer (1x HBS-P with 3 mM 
EDTA); concentration series of 20-80 nM were used for M18 and 10-40 nM for variants.  
All surfaces were regenerated using a 30 second wash with 4 M MgCl2 in running buffer. 
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 Construction of Saturation Mutagenesis Libraries 
Elucidation of the interaction of the 14B7 family of antibodies with PA was 
instrumental in the construction of these libraries.  Previous attempts in our laboratory at 
affinity maturation of an antibody toward the variant PA-Y688A had not met with 
success.  Error-prone libraries of 14B7 and very large saturation mutagenesis libraries 
based upon computational docking models of the antibody-toxin interaction did not yield 
affinity-improved binders (Jeong, K.J., unpublished data).  The approach described here 
utilized the crystal structure of the ultra-high affinity antibody fragment M18 in complex 
with domain 4 of protective antigen of Bacillus anthracis.  Based upon this interaction 
model, residues in definitive spheres of interaction with PAD4-688 were selected for 
saturation mutagenesis.  This approach allowed maximum library diversity to be focused 
on the precise area of contact with PAD4-688. 
With this intention, two libraries were constructed.  The first, denoted NNS3, 
utilized the NNS DNA codon (N signifying any base A, G, C, or T; S signifying G or C) 
to replace wild-type codons in M18 at 3 locations: the two residues that appear to directly 
interact with Y688 of PA (L Q55 and H L101), and the neighboring proline (L P56) that 
might modulate the conformation of the binding region CDR L2.  Likewise, the second 
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library, NNS8, replaced wild-type codons with NNS for 8 residues, which encompass all 
surface exposed amino acids within 6 Å of the Y688 residue of PA (L F46, L Y49, L 
R53, L Q55, L P56, H L101, H L102, and H D107).  This second library included all 
amino acids saturated in NNS3, and added 5 more residues.  After construction by 
overlap PCR and electroporation into MC1061 cells, the NNS3 library exhibited 2 x 107 
individual transformants, while 6 x 107 transformants were observed for the NNS8 
library.  It is important to note that the theoretical diversity at the DNA level for the 
NNS3 and NNS8 libraries were 3.3 x 104 and 1.1 x 1012, respectively.  Therefore, the 
theoretical diversity was covered almost 1000 times by the number of transformants 
produced in the NNS3 library, making it highly likely that every combination of 
mutations was represented at least once in this library.  In contrast, the NNS8 library 
represents, at best, the coverage of 0.005% of the theoretical diversity of an 8-membered 
saturation mutagenesis library.  Ten clones from each library were sequenced, and 
excellent diversity was observed in all expected codons. 
 
3.3.2 Library Sorting 
Prior to the first round of sorting, the NNS3 library was observed to have an 
obvious “tail” feature, while the NNS8 library appeared primarily negative with rare 
positive events.  Both libraries were screened in parallel, and the first three rounds of 
selection were carried out by labeling with 1 µM PAD4-Y688A.  The NNS8 library 
appeared to enrich after two rounds of sorting by the emergence of a tail; significant 
enrichment was observed in both libraries after three rounds of sorting.  Because of this 
enrichment, a more stringent sort with labeling at 20 nM of PAD4-Y688A was carried 
out for the fourth round of sorting.  After the fourth round, analysis was carried out on 




































FIGURE 3.1.  FACS SCREENING OF (A) NNS3 AND (B) NNS8 LIBRARIES.  Y688A 
PAD4 labeling concentration is listed with the round of sorting. 
 
3.3.3 Single Well ELISA Screening 
Two 96-well plates were screened from each library, yielding a total of 384 
individual clones screened (Figure 3.2).  Based upon optimization experiments, the wild-
type scAb M18 would have an absorbance of approximately 1.  43% of clones were 
considered positive (A450 above 0.5), and 36% of clones gave an equivalent or greater 
signal than that expected of M18 (A450 of 1.0 or above).  The top ten percent of clones 
(A450 of 3.0 or above) were submitted for sequencing to determine whether a consensus 
sequence could be identified.  Analysis revealed that these clones from the NNS3 library 
did not converge to a single sequence, as there was still variability among the twelve 
clones.  Interestingly, the 27 clones from the NNS8 library produced several solutions, 
with a consensus forming of L Q55I, L P56S, and H L101M for 20 of 27 clones; 
however, only three of these clones had any variation from wild-type at any of the other 
five locations targeted in the NNS8 library, and this was exhibited as H L102V (CTA  
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GTC) in one clone and a silent codon change at L R53 (AGA  AGG) in two clones.  The 
top nine clones with the greatest absorbances (greater than A450 of 3.9) were well 
separated from the remaining clones.  Thus, these were taken to the next round of 
screening by scale-up expression, purification, and ELISA titration. 
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NNS3-1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.128 2.244 1.510 0.085 0.091 0.095 0.167 3.063 0.129 0.534 2.511 0.103
B 2.098 0.082 4.133 0.648 2.543 0.072 0.128 1.757 0.073 1.434 0.112 1.123
C 0.113 0.080 0.065 0.067 1.149 0.058 0.112 0.083 0.068 0.088 2.194 3.468
D 0.107 2.594 0.479 0.061 1.674 0.060 0.285 0.105 0.195 0.294 2.653 0.066
E 2.343 0.067 0.284 0.302 0.072 0.068 0.134 2.668 0.061 0.078 0.793 0.389
F 0.118 0.070 0.067 0.062 0.183 0.066 1.092 0.120 0.691 0.995 0.065 1.983
G 0.824 0.079 0.068 0.068 0.067 0.109 4.210 1.898 2.367 0.069 2.274 1.016
H 0.313 0.107 0.100 0.132 1.693 1.812 4.186 3.062 0.334 0.082 3.194 0.091
NNS3-2
1 2 3 4 5 6 7 8 9 10 11 12
A 0.149 0.164 2.354 2.837 2.398 0.490 3.189 0.143 0.108 0.117 0.091 0.092
B 0.112 0.091 0.081 0.071 0.583 0.062 0.151 0.080 0.068 0.736 0.066 2.136
C 3.449 0.126 0.065 0.074 0.062 0.064 0.115 0.068 0.803 0.066 0.107 0.066
D 0.110 0.552 0.074 0.069 2.894 0.072 0.099 0.156 2.032 0.075 0.082 0.064
E 0.672 2.820 0.066 0.062 0.072 0.068 0.342 0.064 0.109 0.072 0.403 0.071
F 0.077 0.251 0.067 0.059 0.063 0.754 0.833 0.066 1.432 0.065 1.051 0.077
G 3.383 0.067 0.074 3.326 0.075 0.084 3.749 0.068 1.094 2.992 0.076 0.073
H 0.125 0.097 0.094 0.088 0.079 0.754 0.123 0.101 0.175 1.213 0.075 2.136
NNS8-1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.409 4.305 0.187 0.440 3.423 0.111 2.899 2.289 0.144 0.131 3.331 0.150
B 0.101 0.096 0.096 0.733 0.080 0.077 1.243 0.127 0.862 0.114 0.107 0.093
C 0.191 3.380 3.930 0.107 0.065 0.066 4.010 3.685 0.077 1.295 3.570 3.320
D 0.099 3.264 1.319 0.158 0.069 0.071 0.119 0.089 2.708 0.826 0.278 0.069
E 0.120 0.397 0.073 0.074 2.299 0.087 1.435 3.467 0.084 0.072 0.082 0.083
F 3.778 3.399 1.549 0.086 0.065 0.070 2.929 2.761 0.278 2.705 0.668 2.895
G 0.097 2.255 1.565 2.058 2.695 1.658 2.537 0.403 1.976 0.866 0.096 3.031
H 0.105 1.992 0.093 1.148 0.094 0.077 0.207 0.130 1.560 0.094 1.720 2.514
NNS8-2
1 2 3 4 5 6 7 8 9 10 11 12
A 2.056 4.307 2.764 0.147 0.598 1.295 2.321 0.110 2.090 0.103 0.106 1.000
B 4.200 0.116 1.397 1.575 0.087 0.089 2.808 0.082 3.927 0.075 0.586 2.512
C 0.137 1.558 3.389 0.771 0.086 0.062 3.555 2.250 1.911 0.071 1.633 3.052
D 3.335 1.488 0.080 0.064 4.061 0.100 0.114 0.077 3.087 3.183 1.374 0.078
E 1.672 2.754 3.176 0.063 0.722 0.065 0.880 0.068 0.077 2.287 0.135 2.754
F 3.165 1.119 2.606 0.065 1.889 0.068 1.550 0.067 0.065 1.369 0.071 1.703
G 2.715 0.202 2.599 1.105 0.917 2.579 1.553 0.090 0.075 0.102 1.698 3.421
H 2.273 1.609 1.998 1.245 0.077 0.664 2.737 0.097 0.094 1.083 0.070 0.077
Number of positives
NNS3 NNS8 Total
3 5 8 ≥4
9 22 31 3 - 4
20 29 49 2 - 3
16 34 50 1 - 2
14 12 26 0.5 - 1
130 90 220 <0.5
192 192 384 Total
Percentages
NNS3 NNS8 Total
2 3 2 ≥4
5 11 8 3 - 4
10 15 13 2 - 3
8 18 13 1 - 2
7 6 7 0.5 - 1
68 47 57 <0.5
100 100 100 Total
A B
C
FIGURE 3.2.  SINGLE WELL ELISA SCREENING OF ISOLATED CLONES.  Listed values 
are 450 nm absorbances.  (A) Aggregate data and (B) percentage analysis of (C) actual 
single well ELISA data. 
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3.3.4 Plate ELISA Screening 
 The top nine clones from the previous round of screening were prepared in pure 
form along with M18 scAb, which served as an important control.  When these were 
analyzed for affinity by tittering on ELISA, the observed EC50’s of the mutant clones 
were all better than that of M18 (Figure 3.3).  The best binding curves reflected EC50’s 
of approximately 7-8 fold improved over the wild-type (~10 nM vs. ~70 nM).  The top 
four clones were then examined by surface plasmon resonance (SPR) to determine kinetic 





















FIGURE 3.3.  TITERED PLATE ELISAS FOR THE TOP NINE PAD4-Y688A BINDERS.  (   
   ,       , M18;       ,    X   , no scAb (negative);       , 31B3;    X   , 31G7;    *   , 81A2;    
   , 81C3;    +   , 81C7;    -   , 82A2;    -   , 82B1;       , 82B9;       , 82D5.) 
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3.3.5 Kinetic Studies 
 Initially, all four clones and M18 scAb were screened by SPR to determine their 
kinetic constants with PAD4-Y688A.  Results can be seen in Table 1.  The affinity of 
M18 for PAD4-Y688A was found to be 73.8 nM, more than 2000 times lower affinity 
than M18 binding wild-type PA.  The best of the affinity enhanced clones, 82B9, 
exhibited an apparent affinity of 10.5 nM for PAD4-Y688A, which is approximately 7-
fold better than M18.  SPR analysis was also carried out for M18 and 82B9 interacting 
with full-length PA83-Y688A to confirm that the absence of domains 1-3 did not have any 
unintended effects.  M18 and 82B9 were observed to have affinities of 60 nM and 8 nM, 
respectively, consistent with affinities acquired using PAD4-Y688A.  When the 
interaction between 82B9 and wild-type PA83 was probed, an affinity of 740 pM was 
observed, an approximate 20-fold loss of affinity relative to M18.   
 
3.3.6 Analysis of Clones 
Inspection of the sequences of the 39 highest performing clones (Figure 3.4) in 
the single well ELISA assay revealed that one clone was the result of contamination from 
a neighboring well, as the sequence was that of the negative control, 26-10.  Of the 
remaining 38 clones, twenty displayed the variation L-Q55I, L-P56S, and H-L101M with 
minor variations in sequence throughout.  This represents 53% of total clones sequenced, 
and 74% of clones sequenced from the NNS8 library.  Clones from the NNS3 library 
were much more variable in sequence composition.  However, no additional mutations 
approached fixation within the remaining scFv proteins. 
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Figure 3.4.  Primary sequence of 38 highest clones from the single well ELISA assay.  
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Analysis of the four best variants (Figure 3.5) revealed that increased bulk and 
hydrophobicity were selected at locations L 55, L 56, and H 101.  In fact, in the best 
clone, 82B9, the bulky and hydrophobic amino acids L Q55W and H L101H create an 
aromatic “knob” that most likely fills the space vacated in the Y688A mutation.  Other 
variants incorporated valine or isoleucine at L 55, which are both bulky and hydrophobic.  
Only one of the four clones retained the proline at L 56, and the three best clones had 
substitutions of serine, histidine, and leucine, respectively.  Because proline restricts 
conformation, it appears that the increased flexibility associated with these other amino 
acids is preferable for binding to the Y688A variant. 
It is also interesting to note that while three of the four best antibody variants 
isolated were from the NNS8 library, all four antibodies exhibited completely wild-type 
codons at the DNA level for the five residues covered in the NNS8 library that were not 
in the NNS3 library.  Thus, it is not clear if these three genes were actually selected from 
the initial NNS8 library, or if they were the product of cross contamination from the 
NNS3 library.  While efforts were made at every step to eliminate cross contamination, 
both libraries were sorted and cloned in parallel.  As mentioned earlier, there were clones 
isolated from the NNS8 library within the top 10% of single well ELISA binders that did 
contain diversity in these five codons, which might imply that these four were faithfully 
selected from the NNS8 library and that there was great selective pressure for the wild-
type residues at these locations, although the presence of wild-type codons would be 
highly coincindental.  
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FIGURE 3.5.  PROTEIN SEQUENCES OF FOUR BEST BINDING CLONES FOR PAD4-
Y688A ALIGNED WITH M18.  Framework (FR) and complementarity-determining 
regions (CDR’s) are denoted in gray and black, respectively.  
 
3.4 CONCLUSIONS 
The recovery of 82B9 represents the first affinity improved antibody fragment to 
an altered anthrax toxin.  It is clear that the elucidation of the co-crystal structure of M18 
in complex with PAD4 provided the foundational difference for resolution of this 
problem.  Being able to focus maximum diversity through saturation mutagenesis into a 
very small area yielded the only improvement to date.  The retrieval of several clones that 
exhibit similar selected tendencies, that is hydrophobic, aromatic, and bulky side chains, 
mesh well with the idea that gains in affinity were the result of complementation for the 
loss of the tyrosine on the surface of protective antigen.  While this does represent a 
success, continuing to evolve this clone until a potential therapeutic level (KD ~ 50 pM) is 
reached is still underway.   
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Toward the Engineering of a Photoresponsive Antibody 
 
4.1 INTRODUCTION 
Antibodies have for thousands of years provided protection against disease and 
infection as part of our immune system.  With their high affinities and specificity to their 
intended target, they have proved resilient to some of humankind’s most overwhelming 
illnesses (Lee et al. 2008; Yu et al. 2008).  As scientists and physicians began to 
understand their structure and function, they sought to use them as therapeutics, 
diagnostics, and laboratory reagents, because of the same qualities that made them 
indispensable to the immune system: affinity and specificity.  Currently there are 26 
antibodies approved by the FDA for use as therapeutics or diagnostics for a variety of 
different ailments from Crohn’s disease to cancer (Pavlou and Belsey 2005). 
The creation of a reversible, photoresponsive antibody would be of great utility 
because it would allow both temporal and spatial control of molecular machinery 
utilizing only light.  This could aid in the development of better therapeutics, reusable 
biosensors and protein arrays, and novel reagents in molecular biology.  Recently, a 
photo-activatable antibody was constructed for treatment of cancer utilizing folate-tagged 
anti-CD3 antibodies (Thompson et al. 2008).  Folate binds to cancer cells expressing 
folate receptor, and antibodies to CD3 attract killer T-cells to these cancer cells.  The 
photo-activatable portion of this therapeutic was the appending of 1-(2-
nitrophenyl)ethanol moieties to the antibody that rendered it inactive until they were 
removed upon irradiation with UV light (Self and Thompson 1996).  This is certainly a 
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functional system, but it is not reversible because the antibody cannot be rendered 
inactive after cleavage of the photoactive groups.  A reversible, photoresponsive system 
would provide utility in multiple arenas. 
Previous work has characterized photoisomerizable dyes that can reversibly 
transition between states that differ in shape and polarity (Sakata et al. 2005b; 2005a).  
The nitrospirobenzopyran (BIPS) molecule can reversibly transition between a colorless 
spiro (SP) state and a colored merocyanine (MC) state upon exposure to different 
wavelengths of light.  The SP to MC transition occurs upon irradiation with UV light 
(365 nm), and irradiation with visible light (546 nm) causes transition from MC back to 
the SP state.  If this small molecule could be placed at or near the binding site, perhaps it 
could alter the interaction of antibody with antigen differently in each state, which could 
lead to a differential effect on binding.   
 
Figure 4.1.  Photoisomerization of 8-I-BIPS. 
 
A second approach is to utilize a larger appendage to interrupt binding of 
antibody to antigen.  Previous studies revealed the engineering of “smart” polymer-
protein conjugates that could alter enzymatic activity or streptavidin binding based upon 
polymer structure in response to light modulation (Shimoboji et al. 2001; Shimoboji et al. 
2002a; Shimoboji et al. 2002b; Shimoboji et al. 2003).  The polymer was a co-polymer 
primarily made up of dimethylacrylamide, with azobenzene moieties dispersed 
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throughout.  These polymers exhibited an unfurled state after exposure to one wavelength 
of light, and subsequently underwent aggregation at the protein surface after exposure to 
a second wavelength of light.  This aggregation covered the active site or binding site, 
thus rendering the protein inactive.  Reversion back to the unfurled state restored activity.  
In much the same way, positioning a photoresponsive polymer near the binding site of an 
antibody might allow the specific obstruction of the antibody-antigen interaction. 
The antibody-antigen pair that is to be used in this study is that of the M18 scFv 
with protective antigen (PA) of Bacillus anthracis.  M18 is an ultra-high affinity variant 
from the 14B7 family of neutralizing antibodies directed at PA (Harvey et al. 2004).  
Earlier work has revealed the individual and complex structures of M18 with PA domain 
IV, and the 14B7 family has been amenable to engineering in several systems (Harvey et 
al. 2004; Jeong et al. 2007). 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Optimization of UV Dye Isomerization 
8-Iodo-BIPS was a kind gift from Dr. Gerard Marriott at the University of 
Wisconsin-Madison.  8-I-BIPS was dissolved in dimethylformamide (DMF) at a 
concentration of 10 mM, and then diluted into 1x-HBS-E (10 mM Hepes, pH 7.4, 150 
mM NaCl, 3 mM EDTA) at various concentrations.  An apparatus was constructed to 
provide a consistent scaffold for irradiation of samples with UV light.  A UV hand lamp 
was mounted to an enclosure such that a cuvette could be reproducibly placed at 1 cm 
distance from the center of the light source, while ambient light was blocked.  Samples 
were placed in a quartz cuvette and irradiated with UV light (365 nm) for specified 
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amounts of time, at which point the absorbance at 546 nm was measured with a UV-1600 
UV-Vis spectrophotometer (Shimadzu). 
 
4.2.2 Site Directed Mutagenesis 
M18 variants were constructed using site-directed mutagenesis via overlap PCR.  
The following variants were constructed: H-V93C, H-N59C, H-S75C, L-Q55C, H-
Y100C, L-F46C, L-Y32C, and H-Y52C.  First, two PCR reactions were carried out to 
synthesize two fragments of the gene of interest with the internal primers containing the 
codon changing residue.  These two PCR fragments were purified by agarose gel 
electrophoresis, and mixed together as template for a second PCR reaction to yield the 
full-length gene fragment.  Only the outer primers were used for amplification of this 
second reaction.  Digestion of this fragment was accomplished with SfiI and subjected to 
agarose gel electrophoresis, which was then ligated with pAK400 vector that had 
previously been cleaved with SfiI.  Ligations were desalted using Millipore desalting 
membrane for 1 hr.  Reactions were subsequently transformed via electroporation into 
Jude-1 cells and plated on LB-Agar with 2% glucose and chloramphenicol at 30 µg/mL 
and grown overnight at 37°C.  Individual colonies were picked and grown overnight in 
liquid culture of LB with 2% glucose and chloramphenicol at 30 µg/mL at 37°C.  
Plasmid was isolated from each culture by Miniprep (Qiagen), and sequencing was 
performed on individual clones by the ICMB Sequencing Core Facility. 
After the correct sequence was determined for each construct, plasmid was 
transformed by electroporation into Jude-1 cells, which were plated on LB-Agar with 2% 
glucose and chloramphenicol at 30 µg/mL and grown overnight at 37°C.   Individual 
colonies were picked and grown overnight in liquid culture of LB with 2% glucose and 
chloramphenicol at 30 µg/mL at 37°C.  Frozen stocks were made by mixing liquid 
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culture with 50% glycerol 2:1, for a final glycerol concentration of 16%; cells were 
frozen at -80°C.   
 
4.2.3 Protein Expression and Purification 
Overnight cultures 40 mL in volume of TB with 2% glucose and cloramphenicol 
at 30 µg/mL were inoculated from frozen stocks and incubated at 37°C.  The next day, 
this culture was used to inoculate 1 L of TB with chloramphenicol at 30 µg/mL, which 
was incubated at 37°C for 4 hours, then IPTG was added to 1 mM and induction was 
allowed to continue overnight.  The following morning, cells were pelleted and 
resuspended in 50 mL of 50 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole.  Cells 
were lysed by sonication (Probe dismembrator, Fisher Scientific) on ice in 5 mL aliquots 
by 3 cycles of 30 s at level 5 followed by 30 s off.  Membranes were pelleted by 
centrifugation at 8,000 rpm for 20 minutes.  Supernatant was equilibrated with 1 mL Ni-
NTA Agarose (Qiagen) per liter of culture that had been washed three times in binding 
buffer.  The cell lysate-bead mixture was mixed on ice for one hour.  The Ni-NTA 
agarose beads were washed twice in batch by centrifugation at 3,000 rpm for 5 minutes, 
decanting of supernatant, followed by resuspension in 50 mM Tris, pH 8.0, 500 mM 
NaCl, 20 mM imidazole.  The washed beads were then placed in a disposable 
polypropylene column (Pierce), and protein was eluted by addition of 4- 1 mL fractions 
of 50 mM Tris, pH 8.0, 500 mM NaCl, 250 mM imidazole.  The eluent was dialyzed and 
concentrated into 10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA buffer using an 
Amicon Ultra 15, 10,000 MWCO filter.   
The scFv-containing eluent was then subjected to size exclusion chromatography 
on a Superdex 200 column (GE Healthcare), utilizing a fast performance liquid 
chromatography (FPLC) system (ÄKTA FPLC, GE Healthcare).  Running buffer was 1x 
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HBS-E (10 mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA), flow rate was 0.5 mL/min, 
and 0.5 mL fractions were collected.  Fractions containing monomeric scFv based upon 
the FPLC profile as monitored by the 280 nm UV detector were combined and 
concentrated using an Amicon Ultra 15, 10,000 MWCO filter.  Samples were then 
filtered using 0.22 µm Ultrafree-MC basket filters with PVDF membranes (Millipore).  
Protein concentrations were assessed using the BCA assay (Pierce) with BSA as a 
control. 
 
4.2.4 Expression and Purification of M18-Y52C 
After overnight cultivation of E. coli XL1-Blue containing plasmid pAK400-
M18-Y52C in shake flask, cells were transferred into a 1 L flask containing 150 mL of 
R/2 medium (Jeong and Lee 1999) plus 2% (w/v) glucose. After 8 hr cultivation at 37oC, 
cells were inoculated into fermentor. Fed-Batch fermentations were conducted in a 3.5 L 
Bioflo 300 fermentor (New Brunswick Scientific Co., Edison, NJ) containing 0.75 liter of 
same R/2 medium plus 2% (w/v) glucose.  The pH was controlled at 6.8 by the addition 
of 28% (v/v) ammonia water. The dissolved oxygen concentration (DOC) was controlled 
at 40% of air saturation by automatically increasing the agitation speed up to 1,000 rpm 
and by the change of pure oxygen percentage. Two nutrient feeding solutions were added 
into the fermentor by pH-stat feeding strategy. Firstly, defined feeding solution (700 g/L 
glucose plus 20 g/L MgSO4·7H2O) was used during pre-induction period. When the pH 
rose to a value greater than its set point (6.8) by 0.08 due to the depletion of glucose, the 
appropriate volume of feeding solution was automatically added to increase the glucose 
concentration in the culture broth. Secondly, complex feeding solution (500 g/L glucose, 
100 g/L yeast extract and 20 g/L MgSO4·7H2O) was used for enhancing protein 
production and cell growth during post-induction period.  Before induction, culture 
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temperature was maintained at 37oC but, when cell density reached OD600 of 60, 
temperature was set to 25oC for 30 min and then induction with 1 mM IPTG were done 
and temperatures were maintained at 25oC during post-induction period for correct 
folding of scFv in periplasm.  Cell growth was monitored by measuring the optical 
density (OD) at 600nm using an Ultraspec 3000 spectrophotometer (Shimazu, Japan).  
Culture samples were collected periodically by centrifugation and cell pellets and 
supernatants were stored at -20oC for further analysis. After finishing fermentation, 1.5 L 
culture was collected by centrifugation (6,500 rpm, for 20 min at 4oC) and cell paste was 
stored -20oC for purification of scFv. 
Cells were thawed and resuspended in 1,250 mL of lysis buffer (50 mM Tris, pH 
8.0, 500 mM NaCl, 10 mM imidazole), then they were lysed by two passes through a 
flow-through microfluidics homogenizer set at 10,000 psi.  Cell lysates were then 
centrifuged for 30 minutes at 8,000 rpm, and the scFv-containing supernatant was 
retained.  4 mL of Ni-NTA agarose beads (Qiagen) were pre-washed with lysis buffer, 
and then mixed with the supernatant at 4°C for one hour.  The Ni-NTA agarose beads 
were then collected on a column and washed with 40 mL of lysis buffer.  Purified protein 
was then eluted in 8 mL of 50 mM Tris, pH 8.0, 500 mM NaCl, 250 mM imidazole.  The 
column eluent was then dialyzed against 10 mM Tris, pH 8.0 overnight at 4°C using a 
2,000 MWCO Slide-A-Lyzer dialysis cassette (Pierce). 
The dialyzed sample was then subjected to anion exchange chromatography on a 
Mono Q 5/5 column (GE Healthcare), utilizing a fast performance liquid chromatography 
(FPLC) system (ÄKTA FPLC, GE Healthcare).  The initial running buffer was 10 mM 
Tris, pH 8.0 (Buffer A), and the gradient buffer was 10 mM Tris, pH 8.0 with 800 mM 
NaCl (Buffer B).  The flow rate was 0.5 mL/min throughout, and 1 mL fractions were 
collected during the run.  The sample was injected on to the column and allowed to reach 
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equilibrium with running buffer of 100% Buffer A before a gradient was begun to reach 
20% Buffer B after 50 minutes; pure scFv typically eluted between 8-10% Buffer B 
based upon UV absorbance as monitored by the 280 nm detector .  Fractions containing 
scFv were buffer exchanged and concentrated into 10 mM Tris, pH 8.0 with 150 mM 
NaCl using an Amicon Ultra 15, 10,000 MWCO filter.  Samples were then filtered using 
0.22 µm Ultrafree-MC basket filters with PVDF membranes (Millipore).  Protein 
concentrations were assessed using the BCA assay (Pierce) with BSA as a control. 
 
4.2.5 Conjugation of Small Molecules to Proteins 
8-I-BIPS or 5-iodoacetamidofluorescein (5-IAF) was added to protein solutions in 
a 4- to 8-fold molar excess of protein, and was placed in the dark at 4°C overnight.  Free 
dye was removed by centrifugation for 1 minute at 12,000 rpm followed by thorough 
washing of the supernatant containing protein-dye conjugate with 1x HBS-EP buffer (10 
mM Hepes, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% Polysorbate-20) by 
diafiltration utilizing an Amicon Ultra 15, 10,000 MWCO filter.  Protein concentrations 
were assessed using the BCA assay (Pierce) with BSA as a control, dye concentrations 
were measured at 350 nm (35,000 M-1cm-1) using a Nanodrop 1000 spectrophotometer, 





Figure 4.2.  Structures of 8-I-BIPS (left), and 5-iodoacetamidofluorescein (right). 
 
4.2.6 ELISA Screening of scFv-8-I-BIPS conjugates 
ELISA plate wells were coated with 100 µL of 3 µg/mL PA83 in PBS overnight at 
4°C.  The following morning, the plates were washed with 1x PBS with 0.05% Tween-20 
using a SkanWasher 300 and then allowed to block for 4 hours at room temperature with 
2% milk in PBS.  scFv-dye conjugates, while still in concentrated solution, were given no 
treatment, UV irradiation, or UV irradiation followed by irradiation by visible light.  
They were then diluted to 600 nM in 2% milk-PBS, loaded on to the plate, and subjected 
to 1:1 serial dilutions with 2% milk-PBS across the remaining 11 rows of the plate; 100 
µL was left in each well.  M18 was used as a positive control, and was diluted to 62.5 nM 
in 2% milk-PBS and treated similarly as samples.  This was incubated at room 
temperature for one hour before washing with 0.05% Tween-20 in PBS.  100 µL of anti-
His-tag IgG-HRP conjugate diluted 1:2500 into 2% milk-PBS was applied to each well 
and allowed to incubate at room temperature for 1 hour.  ELISA plates were then washed 
with PBS with 0.05% Tween-20 and developed with 100 µL of TMB substrate.  
Development was quenched by adding 100 µL of 4.5 M H2SO4, mixing gently, and then 
was read at 450 nm using a 96-well plate reader. 
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4.2.7 Temperature Stability ELISA for M18-Y52C 
ELISA plate wells were coated with 100 µL of 3 µg/mL PA83 in PBS overnight at 
4°C.  The following morning, the plates were washed with 1x PBS with 0.05% Tween-20 
using a SkanWasher 300 and then allowed to block for 4 hours at room temperature with 
2% milk in PBS.  M18-Y52C scFv aliquots were placed at a range of temperatures for 15 
minutes, and then diluted to 600 nM in 2% milk-PBS, loaded on to the plate, and 
subjected to 1:1 serial dilutions with 2% milk-PBS across the remaining 11 rows of the 
plate; 100 µL was left in each well.  This was incubated at room temperature for one hour 
before washing with 0.05% Tween-20 in PBS.  100 µL of anti-His-tag IgG-HRP 
conjugate diluted 1:2500 into 2% milk-PBS was applied to each well and allowed to 
incubate at room temperature for 1 hour.  ELISA plates were then washed with PBS with 
0.05% Tween-20 and developed with 100 µL of TMB substrate.  Development was 
quenched by adding 100 µL of 4.5 M H2SO4, mixing gently, and then was read at 450 nm 
using a 96-well plate reader. 
 
4.2.8 Fluorescent Plate Assay for M18-Y52C scFv-IAF Conjugates 
Various concentrations of PA83 were mixed with a set concentration of M18-
Y52C-IAF in a black 96 well plate and allowed to incubate at room temperature for 45 
minutes.  The plate was then read using a BioTek SynergyHT plate reader for fluorescein 
fluorescence with 485/20 nm excitation and 530/25 nm emission. 
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4.2.9 Synthesis of Azobenzene Acrylate Monomer 
The synthesis of 4-phenylazophenyl acrylate was carried out essentially as 
described by Shimoboji et al.  4-phenylazophenol was recrystallized in ethanol and dried 
overnight under vacuum.  Acryloyl chloride was distilled under vacuum, and 
triethylamine was distilled prior to use.  Dry diethyl ether was obtained from a solvent 
delivery system.  0.2 mol of 4-phenylazophenol and 0.26 mol triethylamine were 
dissolved in 200 mL diethyl ether and placed under argon at 0°C.  0.24 mol acryloyl 
chloride was added dropwise while stirring, then the ice bath was removed and the 
reaction was allowed to equilibrate to room temperature overnight.  The reaction was 
then filtered to remove triethylammonium salts, washed with base, water, and brine, then 
dried with sodium sulfate and filtered.  The remaining solution was evaporated and 1H 
NMR in deuterated-DMSO confirmed the presence and purity of product.  1H NMR 
(DMSO) δ 7.95 (m, 2H), 7.87 (m, 2H), 7.57 (m, 3H), 7.41 (m, 2H), 6.56 (dd, Jlarge = 17.2 
Hz, Jsmall = 1.2 Hz, 1H), 6.42 (dd, Jlarge = 17.2 Hz, Jsmall = 10.4 Hz, 1H), 6.17 (dd, Jlarge = 
10.4 Hz, Jsmall = 1.2 Hz, 1H) ppm.  Product was stored at -20°C in the dark to await 
further use. 
 
4.2.10 Synthesis of Azobenzene-Dimethylacrylamide Co-polymer 
Again, synthesis of this polymer was modeled after the synthesis of Shimoboji et 
al.  Dimethylacrylamide, the co-polymer monomer, and β-mercaptoethanol, the chain 
transfer reagent, were distilled under reduced pressure immediately prior to use.  2,2’-
azobisbutyronitrile (AIBN), the radical initiatior, was recrystallized from acetone and was 
a kind gift of the laboratory of Dr. Grant Willson.  Dry dimethylformamide was obtained 
from a solvent delivery system.  As this was a co-polymer, the total monomer 
concentration (4-phenylazophenol acrylate and dimethylacrylamide) was 2 M, and the 
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basic ratio of monomer:AIBN:β-mercaptoethanol was 100:1:0.2 for all syntheses.  The 
reaction was prepared and then subjected to three cycles of freeze-pump-thaw to remove 
oxygen from solution; it was then placed at 60°C under argon for 20 hours to polymerize.  
The reaction was then either evaporated and solubilized in tetrahydrofuran (THF), or 
mixed 1:1 with THF and precipitated into 10 volumes of 33% diethyl ether in hexanes 
(v/v); the reaction was then filtered and dried under vacuum overnight.  Gel permeation 
chromatography was utilized to determine the molecular weight of the polymer, and 1H 
NMR in deuterated-DMSO was used to reveal the percent incorporation of the 
azobenzene monomer within the co-polymer by comparing the ratio of the proton 
integrations of aliphatic to aromatic signals, while subtracting out signals due to the 
protons in the acrylic backbone based upon their prevalence in the monomers.  Co-
polymers were stored in the dark at room temperature awaiting further use. 
 
4.2.11 Synthesis of Vinyl Sulfone-capped Co-polymer 
Co-polymer synthesized with the aid of the chain transfer agent β-
mercaptoethanol contained a terminal hydroxyl group on one end of the polymer.  
Divinyl sulfone was reacted with that hydroxyl group in order to append a moiety that 
could covalently attach to a free cysteine located on a protein.  Approximately 1 gram of 
co-polymer was dissolved in 20 mL of either dichloromethane or THF with 10-fold molar 
excess of divinyl sulfone and 2.5-fold molar excess of potassium tert-butoxide.  The 
solution was allowed to react under argon while stirring overnight at room temperature.  
Reactions in dichloromethane were evaporated and solubilized in THF; then, the reaction 
solution in THF was precipitated into 10 volumes of 33% diethyl ether in hexanes (v/v), 
filtered, and dried overnight under vacuum.  Gel permeation chromatography was utilized 
to determine the molecular weight of the co-polymer, and FT-IR was used to confirm the 
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presence of a sulfone in the co-polymer.  The product was then stored in the dark at room 
temperature while awaiting use.  
 
Figure 4.3.  Structure of vinyl sulfone-capped co-polymer, with the respective precursor 
groups labeled below. 
 
4.2.12 Lower Critical Solution Temperature (LCST) Measurements 
Co-polymer was dissolved in aqueous solvent at a concentration of 2mg/mL, 
loaded into a microcuvette, and exposed to visible or UV light.  LCST measurements 
were then made on samples using a Beckman DU 700 UV-Vis spectrophotometer with a 
peltier temperature controlled cuvette holder.  Data was collected for 600 nm absorbance 
at 0.2°C increments, and a temperature gradient of 0.5°C/min was maintained throughout. 
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 Optimization of UV Dye Isomerization 
In order to carry out photoisomerization studies with 8-I- BIPS appended to 
proteins on a free cysteine, it was necessary to first understand how this dye responded to 
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UV light using our instrumentation.  The photoisomerization of this molecule has been 
carried out extensively in previous work (Sakata et al. 2005b; 2005a).  Irradiation with 
UV light results in scission of a C-O bond, which induces an absorbance in the visible 
range and makes the compound colored.  Irradiation with visible light causes reversion 
back to the uncolored state.  Analysis in this laboratory revealed that an exposure to UV 
light for 2 minutes resulted in greater than 90% conversion of dye to the colored state; 






















FIGURE 4.4.  UV OPTIMIZATION OF 8-I-BIPS PHOTOISOMERIZATION, by 
concentration of 8-I-BIPS listed here.      , 5 µM;     , 7.5 µM;     , 10 µM;   X  , 15 µM;   
*  , 20 µM. 
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4.3.2 Protein Expression and Purification 
Eight variants of M18 were constructed with an additional cysteine placed using 
site-directed mutagenesis: H-V93C, H-N59C, H-S75C, L-Q55C, H-Y100C, L-F46C, L-
Y332C, and H-Y52C.  These mutations were placed at locations around the antibody 
fragment to determine a location optimal for manipulation of the antibody affinity by the 
photoreactive group.  Of note, H-Y100C was in the center of bindng site, and H-Y52C 
was at the edge of the binding site with PA.  With the addition of this extra cysteine, it 
was hypothesized that additional misfolding might occur, which could decrease the 
protein yield.  This appeared to be the case, because mutation of M18 scFv, which 
routinely yields 4-8 mg/L of culture, resulted in variants that routinely produced less that 
0.1 mg/L of culture.  Because of the poor yields, it was at times necessary to carry out 
multiple preparations of a given protein in order to characterize it in more than one assay.  
It was also observed that levels of contaminating proteins within preparations could vary, 
such that an alternate form of purification might be preferable for additional studies. 
 
4.3.3 Expression and Purification of M18-Y52C scFv 
While hampered in earlier efforts with poor protein production, a fermentor was 
utilized to produce a greater amount of protein to prevent the time consuming effort and 
variation in purity of preparations that were prevalent using other techniques.  A 
retrospective analysis is presented in Figure 4.5 for the preparation of M18-Y52C 






















































1 mM IPTG induction
 
Figure 4.5.  Analysis of M18-Y52C scFv fermentor run. 
 
As observed in previous preparations, contaminating proteins hindered the 
isolation of pure M18 variants.  Protein sequencing revealed the identity of contaminant 
proteins (glmS and slyD), and the isoelectric point of each of the contaminants was 
computationally determined to reside between 5 and 6.  The M18 scFv and its variants 
exhibit a significantly higher pI between 7 and 8.  The disparity of isoelectric points was 
utilized by anion exchange chromatography to remove these contaminants to yield pure 
M18-Y52C.  The final yield of M18-Y52C was 21.4 mg from 1.25L of culture.  This 
purification was carried out under limiting Ni-NTA agarose bead conditions to maintain 
maximum purity, but it appears based upon the retrospective analysis that less than 20% 
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of the total M18-Y52C was recovered.  However, 21.4 mg of protein was more than 
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FIGURE 4.6.  PAGE ANALYSIS OF M18-Y52C PROTEIN PURIFICATION.  Lane labels: 
M- molecular weight marker; 1- pre-Ni-NTA soluble fraction; 2- insoluble fraction; 3- 
Ni-NTA column flow-through; 4- Ni-NTA column wash 1; 5- Ni-NTA column wash 2; 
6-13- Ni-NTA column elutions 1-8; 14 and 15- M18-Y52C after ion exchange 
chromatography. 
 
4.3.4 Conjugation of Small Molecules to Proteins 
Both compounds that were to be appended to proteins were iodinated, so an SN2 
reaction with a free cysteine should proceed spontaneously, given that the sulfur is in a 
deprotonated state.  The pKa of cysteine is 8.3, so the reaction was carried out in buffer 
with pH as close to that as possible (pH of 7.4 to 8.0) to increase efficiency of attack.  
While it was expected that reactions of cysteines placed in different locations might have 
different efficiencies of conjugation, and this appeared to be the case, these conjugation 
efficiencies are very rough approximations and do not carry much meaning.  When the 
M18 variants H-V93C, L-Q55C, and H-Y100C were coupled with 8-I-BIPS they yielded 
25%, 23%, and 30% conjugation efficiencies, respectively; when H-Y52C was coupled 
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with 5-IAF it yielded 18% conjugation efficiency by the ratio of spectroscopically 
determined dye concentration to the protein concentration determined by BCA assay.   
 
4.3.5 ELISA of 8-I-BIPS Conjugates 
It was found that when careful titration using multi-channel pipettes and 
utilization of the SkanWasher 300 for washes were combined during ELISA, that plate-
to-plate variation was minimized on a given day.  It appeared that H-N59C and L-Q55C 
exhibited reproducible changes in ELISA binding curves when exposed to UV light 
relative to non-irradiated samples.  When subsequently exposing L-Q55C to visible light 
in order to restore the BIPS dye to its three-ringed “ground” state, there appeared to be no 
reversion to the untreated curve.  However, H-Y100C, which is located directly in the 
binding interface of the M18-PA complex, did appear to have a slight light-dependent, 
reversible effect based upon ELISA binding curves.  This effect seemed to be 
















































































FIGURE 4.7.  ELISA CURVES FOR SCFV-BIPS CONJUGATES.  (A) Controls:      , M18 
scFv (positive);     , Negative;   +  , N59C unconjugated;   -  , N59C unconjugated + UV.  
(B) N59C-BIPS:     , no treatment;     , UV.  (C) Q55C-BIPS:     , no treatment;     , 
UV;     , UV + Vis.  (D) Y100C-BIPS:     , no treatment;     , UV;     , UV + Vis. 
 
This effect is likely negligible because it was an attempt to utilize a relatively 
small molecule with a slight structural deviation to effect a quantifiable change on a large 
binding surface.  In light of this, the use of a much larger photoactive moiety was 
intended to prevent problems associated with the earlier approach.  Earlier work 
undertaken at the University of Washington indicated the synthesis of photoactive 
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polymers that could be appended to proteins might be a valid approach (Shimoboji et al. 
2002a; Shimoboji et al. 2002b).  To begin this effort, a location on the M18 scFv was 
sought after that would be suitable for the placement of such a polymer. 
 
4.3.6 Plate Assay for M18-Y52C-IAF 
Based upon crystallographic studies of the M18-PA binding interface, it was 
determined that the heavy chain residue Y52, which resides at the beginning of the CDR 
H2 loop, might be a residue that would be close enough to the binding site to allow the 
photoresponsive polymer to interrupt the interaction between M18 and PA while not 
abrogating binding completely.  Because these are also requirements for a fluorescent 
environmental sensor (Owenius et al. 1999; de Lorimier et al. 2002; Renard et al. 2003; 
Thomas et al. 2006), the successful development of a PA-detecting fluorescent sensor 
utilizing the M18 scFv scaffold might be used to determine whether H-Y52C would be a 
suitable candidate for location of the photopolymer.  
After scale-up, purification of M18-Y52C, and conjugation to 5-IAF, ELISA was 
carried out on the unconjugated and conjugated forms of M18-Y52C to verify that there 
was still adequate binding activity.  Then, a constant amount of M18-Y52C-AF was 
aliquoted into a 96 well plate and mixed with varying concentrations of PA in order to 
determine whether differential fluorescence could be observed based upon PA 
concentration.  While trying to correct for the amount of fluorescence added into each 
well when using different protein-fluor preparations, a titration curve was reproduced 
using fluor-protein conjugate made from different protein preparations and conjugation 
reactions.  Initial single concentration optimization experiments revealed that 970 nM 
M18-Y52C-AF conjugate exhibited differential fluorescence in the presence of 1.1 µM 
PA, while an equal concentration of BSA did not have an effect.  With a probable 
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location for conjugation of the photopolymer identified, synthesis of a suitable 
photopolymer was undertaken after temperature stability was determined for the M18-

























































FIGURE 4.8.  ENVIRONMENTAL BIOSENSOR ACTIVITY OF M18-Y52C-AF.  Left: 
Optimization of environmental sensor at () 0.97 µM M18-Y52C-AF mixed with 1.1 µM 
of PA or BSA; () 0.92 µM M18-Y100C-AF (non-sensing) with 1.1 µM of PA or BSA 
for comparison.   Right: Environmental biosensor M18-Y52C-AF with several 
concentrations of PA83. 
 
4.3.7 Temperature Stability of M18-Y52C scFv 
 An ELISA assay to determine the maximum temperature for an experiment using 
M18-Y52C was developed because of the nature of the photopolymer that would be used.  
UV irradiation causes an upward shift in the LCST of the polymer with respect to 
polymer irradiated with visible light.  This LCST is a measurement of aggregation of the 
polymer, and the differential effect of light irradiation is elicited through the trans to cis 
transition of azobenzene with UV irradiation, with the cis form causing the LCST 
transition to occur at a higher temperature (Shimoboji et al. 2002a).  The utility of a 
photo-reactive transition between the two states of linear to aggregated polymer could 
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then be carried out at a constant temperature just below where aggregation begins to 
occur for the UV irradiated polymer.  In that case visible irradiation would cause 
precipitation of the polymer which might then block the binding site of the M18-Y52C 
scFv, rendering it unable to bind PA; subsequent irradiation with UV light would restore 
the polymer to its linear form and allow the scFv to bind PA.  In order to determine the 
























FIGURE 4.9.  TEMPERATURE STABILITY ELISA OF M18-Y52C AT 15 MINUTES 
EXPOSURE TO EACH TEMPERATURE.      , 25oC;     , 30oC;     , 37oC;   X  , 45oC;   *  , 
55oC;     , Negative. 
 
 130 
Analysis of the ELISA determined that a maximum of 15 minutes at 45oC could 
be sustained by the antibody fragment; in fact, precipitation was observed in the 45oC 
sample when mixing with milk-PBS to apply to the ELISA plate.  It is inferred that more 
time at that temperature would presumably render the scFv inactive.  Therefore, it would 
be preferred that the isotherm at which an experiment were run at would be below 40oC, 
and lower temperatures than this would be preferable. 
 
4.3.8 Synthesis of Azobenzene-Acrylate Monomer 
Utilizing Shimoboji et al. as a guide, synthesis of the ester-linked azobenzene-
acrylate monomer was quite straightforward.  The reaction occurring was of an acid 
chloride with an alcohol to create an ester.  The only alteration from the previous protocol 
was that recrystallization after formation of the acrylate monomer was omitted, because 
unwanted polymerization appeared to occur upon heating of the monomer in ethanol.  
Characterization by 1H-NMR agreed well with the expected 
product.
 
Figure 4.10.  Synthesis of 4-phenylazophenyl acrylate. 
 
4.3.9 Synthesis of Azobenzene-Dimethylacrylamide Co-polymer 
Synthesis of the co-polymer required more alterations to the originally published 
protocol than synthesis of the azobenzene monomer.  Polymerization conditions were 
maintained essentially as described in Shimoboji et al., with the addition of three freeze-
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pump-thaw cycles after preparation of the reaction.  Following polymerization, 
precipitation using previously described conditions was found to be insufficient.  
Evaporation followed by resuspension in THF or dilution 1:1 in THF followed by 
precipitation into 1:2 diethyl ether:hexanes produced much more efficient precipitation of 
the co-polymer.  1H-NMR revealed approximately 10% incorporation of the photoactive 
azobenzene monomer into the co-polymer utilizing the reaction composition of the earlier 
work, and gel permeation chromatography (GPC) analysis yielded Mw=26,900 and 
Mn=13,200.  LCST analysis revealed a steep A600 curve that began to rise from baseline 
at approximately 48oC, and UV irradiation caused a successful shift of the A600 curve to 
roughly 55oC in 10 mM Tris, pH 8.0.  While this represented a successful construction of 
a photoresponsive co-polymer, it was not a polymer that conformed to the temperature 
constraints of the M18-Y52C scFv.   
Previous studies in dimethylacrylamide co-polymers reveal that in order to lower 
the LCST, an increase in the aromatic monomer incorporation is necessary (Miyazaki and 
Kataoka 1996).  Therefore, an attempt to increase incorporation to 15% was initiated.  
This was accomplished by increasing the amount of monomeric azobenzene-acrylate 
ester in the polymerization reaction.  GPC analysis revealed Mw=20,900 and Mn=12,700, 
while 1H-NMR yielded a molar incorporation of 18% for azobenzene monomer.  This 
polymer was so hydrophobic that it could not be dissolved in aqueous buffers at room 
temperature and a concentration of 2 mg/mL for LCST testing at this stage, although 
more polymer appeared to dissolve into aqueous buffer when the undissolved suspension 
was placed at 4oC.  This might imply that the LCST is lower than room temperature for 

























Figure 4.11.  LCST curves for co-polymer with 10% azobenzene monomer incorporation. 
    , visible irradiated;     , UV irradiated. 
 
4.3.10 Synthesis of Vinyl Sulfone-capped Co-polymer 
Polymer that was synthesized in the previous step was purposefully made using 
the chain transfer agent β-mercaptoethanol so that a hydroxyl group would reside on one 
of the ends of the polymer chains.  Divinyl sulfone was reacted in a Michael addition in 
high molar excess to place the vinyl sulfone as an end group which will allow the 
polymer chains to append to a free cysteine on a protein.  Potassium tert-butoxide was 
used to quantitatively deprotonate the hydroxyl, which should then react by attacking one 
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of the alkenes in 1,4 addition fashion.  Reactions were carried out overnight at room 
temperature in DCM or THF, and the choice of solvent did not seem to have an effect 
over that duration.  Precipitation conditions had to be altered from Shimoboji et al., as 
DCM precipitated into diethyl ether was not optimal.  Yield from each reaction was 80-
90% for both 10% and 15% azobenzene monomer-incorporated polymers, and sulfone 
bands were observed using FT-IR, which were not present before the addition.  However, 
GPC analysis of each polymer revealed molecular weights significantly lower than those 
of the original co-polymers.  Mw=8,600 and Mn=5,200 were observed for the vinyl 
sulfone-co-polymer with 10% incorporation (VS-10), and Mw=11,600 and Mn=5,900 
were obtained for the 18% azobenzene incorporation co-polymer (VS-18).  LCST curves 
revealed the initial aggregation for visible light-irradiated polymer of both VS-10 and 
VS-18 were at approximately 58oC.  UV irradiation of the VS-10 polymer gave a 
characteristic upward shift of aggregation initiation to approximately 63oC, while similar 
treatment of the VS-18 polymer actually decreased the initial aggregation temperature to 












































FIGURE 4.12.  LCST CURVES FOR VINYL SULFONE-CAPPED CO-POLYMERS.  (A) VS-
10:     , visible irradiated;     , UV irradiated.  (B) VS-18:     , visible irradiated;     , UV 
irradiated.   
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While it is possible that capping with vinyl sulfone caused the apparent molecular 
weights to shift downward by GPC, this was such a significant shift that it is not likely to 
be the case.  Other possibilities are that there is actually cleavage of the polymer 
backbone during the reaction, or that the precipitation conditions are selectively 
precipitating only the lower molecular weight polymer chains.   
 
4.4 CONCLUSIONS 
The purpose of this work is to move toward the creation of a generalizable 
engineering solution to the challenge of producing a photoresponsive antibody.  In this 
study, two different attempts at photoresponsive elements were utilized.  First was the use 
of a photoisomerizable small molecule at the binding interface, and the second was the 
synthesis of a photoreactive polymer that would cover the binding interface.  The former 
system yielded equivocal results, and it is probable that requiring a small molecule to 
alter the binding interface in a significant way so as to perturb the interaction was 
energetically beyond the reach of the system.  The latter system appears to show some 
promise as the photoreactive polymer could be reproduced and yielded differential LCST 
curves for visible- and UV-irradiated samples.  However, several hurdles need to be 
cleared in order to bring this system to fruition.  First, a polymer must be synthesized that 
meets the temperature needs of the M18-Y52C scFv, which is an assay temperature of 
less than 40oC and preferably very close to room temperature.  It must also have 
differential response to UV and visible irradiation.  This will most likely require an 
empirical approach utilizing the previous conditions as guidelines for synthesis of the 
next round of co-polymers.  Second, conditions for precipitation of the polymer after 
appending the vinyl sulfone moiety must be optimized such that the distribution of 
molecular weights of the polymer is not skewed significantly in the process.  If this is not 
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the reason for decrease in molecular weight, then additional insight is needed to resolve 
the basis for this decline.  Despite the intrinsic difficulties of working through these 
obstacles, the use of photoresponsive polymers appears to hold great promise for the 
application to modulation of antibody binding based upon its successes in other systems. 
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Structure and Function of an RNA Thermosensor in Yersinia pestis 
 
5.1 BACKGROUND 
Yersinia pestis is a gram negative pathogenic bacterium that is the causative agent 
of plague.  It is estimated to have killed approximately 200 million people over recorded 
history, and in the mid 14th century it wiped out approximately 40% of the European 
populace (Duplaix 1988).  Outbreaks as recently as 1994 reveal that Y. pestis is still a 
health threat, and its ability to cause fear and panic make it an ideal agent for bioterrorism 
attacks (Perry and Fetherston 1997).   
Y. pestis persists through cyclic infection of rodents and their fleas.  Over 31 
species of fleas have been proven to be vectors, while it is thought that any of the other 
1,500 species could carry the bacterium under the proper conditions (Perry and 
Fetherston 1997).  It is also known that over 200 mammalian species can become 
infected by the bacterium (Perry and Fetherston 1997).  Mammalian blood can contain 
high concentrations of bacteria during infection, which are passed to fleas when they feed 
on their mammalian hosts.  The bacteria then create an obstruction in the proventriculus 
of the flea, which prevents the flea from feeding.  However, these fleas then try to feed 
continually, and transmit Y. pestis to another mammalian host while doing so (Bacot 
1914).  Rodents are the primary mammals utilized in the transmission cycle of Y. pestis, 
while humans usually represent an unproductive infection for the bacterium. 
Mammalian virulence of Y. pestis, and related pathogenic species Y. 
enterocolitica and Y. pseudotuberculosis, are very complex.  Approximately 50 genes are 
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involved.  These genes are located on a roughly 70 kb plasmid, named pCD1 in Y. pestis 
(Hu et al. 1998; Perry et al. 1998).  Virulence effectors, secretion machinery, 
translocation machinery, chaperones, and virulence regulators are all encoded within this 
virulence plasmid (Konkel and Tilly 2000).  In general, effector proteins are named as 
Yops (“Yersinia outer protein”), secretion machinery are labeled as Yscs (“Yop 
secretion”), and chaperones are regarded as Sycs (“Specific Yop chaperone”).   
Approximately half of the virulence genes are under the control of LcrF, a 
member of the AraC transcription activator family (Cornelis et al. 1998).  The members 
of this family comprise two groups, catabolic regulators and virulence regulators.  LcrF is 
a 31 kDa protein that exhibits a remarkable 98% similarity to VirF of Y. enterocolitica 
(Hoe et al. 1992).  These proteins have a putative helix-turn-helix motif, which is 
implicated in DNA binding (Caron et al. 1989).  Expression of both of these proteins is 
also regulated by temperature.  At low temperatures around 26oC, expression is very low, 
while protein levels are markedly higher at 37oC.  This temperature switch is thought to 
be the main regulatory mechanism by which the bacterium is alerted that it is in its 
mammalian host. 
Two different models have been put forth for the temperature regulation of LcrF 
and VirF.  First, VirF transcription in Y. enterocolitica is thought to be controlled by bent 
DNA (Rohde et al. 1999).  At low temperatures, the intrinsic bend prevents transcription, 
while shifting the temperature up to 37oC relieves the bent structure, allowing 
transcription to occur.  The second model, from Y. pestis, speculates that RNA secondary 
structure within the 5’ UTR of the lcrF mRNA sequesters the Shine-Dalgarno (SD) 
sequence at low temperatures, preventing translation.  At 37oC, the secondary structure 
unfolds and allows translation to take place (Hoe and Goguen 1993).   
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The first model has been experimentally tested in Y. enterocolitica, and it appears 
to have merit.  Other systems that seem to exhibit this type of control appear in Shigella 
and E. coli (Tanaka et al. 1991; Prosseda et al. 2004).  Previously, temperature regulation 
of LcrF by an RNA thermosensor was proposed as a theoretical model in 1993, and it has 
remained untested for more than 10 years.  Other organisms that have been found to use 
this type of control are E. coli, Listeria monocytogenes, and Bradyrhizobium japonicum 













FIGURE 5.1.  POST-TRANSCRIPTIONAL PROTEIN REGULATION OF LCRF.  RNA 
thermosensor model of Yersinia pestis LcrF post-transcriptional regulation.  At low 
temperatures, the RNA hairpin prevents the ribosome from binding the Shine-Dalgarno 
(SD) sequence.  At higher temperatures, the hairpin unfolds and allows access to the 
ribosome.  Adapted from Johansson et al., 2003. 
 
Although the LcrF RNA thermosensor has never been analyzed for these 
properties, it is widely proposed that LcrF protein expression is modulated by this post-
transcriptional phenomenon, even being included as a foundational member of a class of 
RNA thermometers (Waldminghaus et al. 2007).  There is also speculation that both 
mechanisms could function together to regulate LcrF/VirF at both the transcriptional and 
translational level (Cornelis et al. 1998).  Although there is evidence that post-
transcriptional regulation is occurring, a rigorous test of the validity of an LcrF RNA 
thermosensor model should be carried out before it becomes so firmly rooted in dogma.   
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5.2 MATERIALS AND METHODS 
 
5.2.1 Construction of Plasmids 
The 5’ UTR of LcrF (NCBI Nucleotide accession number M86690, Hoe et al. 
1992) was constructed using PCR with overlapping primers (Sandhu et al. 1992), and 
placed on the N- terminus of GFPm2 (Tabor et al. 2008) with 24 nucleotides from 
pGFPUV (ATGACCATGATTACGCCAAGCTTT, Clonetech) in between.  This 
construct was introduced into the arabinose-inducible, ampicillin resistant pBAD18 
vector (Guzman et al. 1995) between the KpnI and SphI restriction sites of the Multiple 
Cloning Site (MCS) to create pBAD18-LcrF-GFP.  Mutants 1, 2, 3, 5, 6, 7, and G178C 
were constructed using the QuikChange® procedure (Stratagene).  pBAD33-CFP was 
created by inserting the eCFP gene with a strong ribosomal binding site from the MIT 
registry of standard biological parts (http://parts.mit.edu, part number BBa_I15012) at the 
KpnI site and sequencing to confirm proper orientation. 
 
5.2.2 In-line Probing 
RNA structure assays utilizing in-line probing were performed on the wild-type 
LcrF 5’ UTR.  PCR was utilized to create the template for run-off transcription by 
amplifying with primers truncating the 5’ UTR for optimal resolution based upon 
optimization of the assay.  The forward primer introduced a T7 promoter 
(lcrF.gfpm2b.inline.F, 
TTCTAATACGACTCACTATAGGGCATAATAACTCAATACA) and the reverse 
primer truncated the transcript at the first codon of GFPm2 (lcrF.gfpm2b.inline.R, 
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CATAAAGCTTGGCGTAATCAT).  PCR products were transcribed using a T7 RNA 
transcription kit (Epicentre).  The resulting RNA was purified by denaturing 
polyacrylamide gel electrophoresis (PAGE), dephosphorylated, radiolabeled using T4 
polynucleotide kinase (NEB), and subjected to a second round of denaturing PAGE.  In-
line probing was performed at 25°C for 48 hours and at 37°C for 24 hours, resolved by 
denaturing PAGE, and imaged using a phosphorimager. 
 
5.2.3 Fluorescence Assays 
Jude-1 cells (Kawarasaki et al. 2003) were electroporated with one of the 
pBAD18-LcrF-GFP variants in combination with pBAD33-CFP and plated on selective 
media (100 µg/mL ampicillin and 30 mg/µL chloramphenicol).  Colonies were picked, 
grown in liquid culture overnight at 37°C, and frozen at -80°C in LB with 15% glycerol.  
Frozen stocks were used to inoculate 3 mL cultures of LB selective media and were 
grown overnight at 37°C.  These cultures were placed on ice for 15 minutes and used to 
inoculate inducing media (LB with 0.2% arabinose, 100 µg/mL ampicillin, and 30 mg/µL 
chloramphenicol) or non-inducing media (LB with 100 µg/mL ampicillin and 30 mg/µL 
chloramphenicol) at an OD of 0.05.  Samples were grown in triplicate in a 96 well plate 
and monitored in real-time for OD at 600 nm, GFP fluorescence, and CFP fluorescence 
using a Synergy-HT plate reader (Bio-Tek) at specified temperatures.  Fluorescence 
results from the onset of stationary phase were utilized for analysis. 
 
5.2.4 Real-Time PCR Assays 
Samples were subjected to similar treatment for fluorescence assays at 25°C and 
37°C and then placed at -80°C to prevent RNA degradation until processing.  RNA was 
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isolated using an RNeasy mini kit (Qiagen) in conjunction with DNase digestion to 
eliminate DNA contamination of samples.  Reverse transcription of the samples to 
produce cDNA was carried out using SuperScript II reverse transcriptase (Invitrogen) 
with a mixture of the reverse primers of the real-time PCR sets for each gene.  Real-time 
PCR assays were performed in triplicate for each sample using an Applied Biosystems 
7900HT real-time PCR machine for GFP, CFP, and 16S rRNA.   2x qPCR master mix 
(Applied Biosystems) and 1 ng of cDNA template was used for each reaction, and 
primers and probes for each gene are listed.  GFP forward primer- 
GATGGCCCTGTCCTTTTACCA, GFP reverse primer- 
TTTTCGTTGGGATCTTTCGAA, and GFP Taqman probe- 
6FAM/ACAACCATTACCTGTCCACACAATCTGCC/BHQ1; CFP forward primer- 
CATCGACTTCAAGGAGGAC, CFP reverse primer- CTTGATGCCGTTCTTCTG, and 
CFP Taqman probe- 6FAM/GTACAACTACATCAGCCACAACGTCTATAT/BHQ1; 
16S rRNA forward primer- CGTGTTGTGAAATGTTGGGTTAA, 16S rRNA reverse 
primer- ACCGCTGGCAACAAAAGATAA, and 16S rRNA Taqman probe- 6FAM/ 
TCCCGCAACGAGCGCAACC/BHQ1, where BHQ1 is Black Hole Quencher 1 
(Integrated DNA Technologies).  The ratio of Cycle Threshold values (C(T)s) at 25°C 
and 37°C of the 16S rRNA were used as a multiplier to normalize GFP and CFP C(T)s.  
Average C(T) values reported for each sample were calculated from 3 independent 
cultures grown in parallel.  
 
5.3 RESULTS AND DISCUSSION 
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5.3.1 In-line Probing 
Hoe and Goguen uncovered indirect evidence of posttranscriptional regulation of 
LcrF in 1993.  Our initial direction was to show structural proof of a hairpin that 
occluded the Shine-Dalgarno region of the LcrF 5’ UTR that was predicted from our 
mfold calculations.  We chose to use in-line probing as our method of detection.   
RNA bases that are in unstructured regions (i.e., single stranded RNA) will be 
susceptible to a spontaneous 2’-3’ cyclic phosphate transesterification of the RNA 
backbone, which is the normal method of RNA degradation (Fig. 5.2).  This cleavage 
reaction can occur when the 2’ hydroxyl of the ribose lies in the same plane as the 
adjacent P-O 5’ bond.  RNA bases lying in an A-form helix are prohibited from adopting 
the “in-line” conformation and are resistant to this cleavage.  Hence, unpaired bases are 
represented by bands present in denaturing PAGE, and absence of banding represents 
double stranded RNA. 
 
FIGURE 5.2.  MECHANISM OF IN-LINE PROBING.  The 2’ hydroxyl group attacks the 3’ 
phosphate group when the 5’ P-O bond of the next base is in the same plane as the 2’ 
hydroxyl, with the downstream base acting as the leaving group.  This is how 
spontaneous degradation of RNA occurs.  Adapted from Soukup and Breaker, 2003. 
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In-line probing was carried out on 32P-end labeled RNA as described previously 
(Soukup and Breaker 1999; Winkler et al. 2002; Sudarsan et al. 2003).  Alkaline 
hydrolysis (every base) and RNase T1 (G-specific) cleavage ladders were prepared using 
protocols from Soukup and Breaker (Soukup and Breaker 1999).  Predicted and actual 
data are shown below, and they coincide very well (Figure 5.3).  Increased banding of the 
37°C sample was not observed as was hypothesized, although this is not inconsistent with 







FIGURE 5.3.  IN-LINE PROBING OF THE LCRF 5’UTR.  Actual results are to the left, 
boxed in red for emphasis.  Predicted results are to the right, with a stem-loop structure 
illustrated to aid interpretation.  Lanes 1 and 7-RNase T1 digested; Lanes 2 and 6-
alkaline hydrolysis; Lane 3-no digestion; Lane 4-25oC; Lane 5-37oC. 
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5.3.2 Fluorescence Assays 
In order to determine whether the lcrF 5’ UTR behaved as a thermosensor, it was 
necessary to make mutations to the stem-loop structure that would have predictable 
outcomes if the structure was in fact sensing temperature and folding accordingly.  We 
made 7 mutant forms of the thermosensor which would have a destabilizing, stabilizing, 
or no effect on the stem loop structure (Figure 5.4).  Destabilizing mutants should exhibit 
higher protein expression at lower temperatures, while stabilizing mutants should have 
low protein expression at both low and high temperatures. 
 
Figure 5.4.  LcrF 5’ UTR Mutants. 
 
A reporter system was constructed for our purpose.  The lcrF 5’ UTR and the 7 
mutants were placed upstream of GFP mutant 2b in pBAD18, while eCFP was cloned 
into pBAD33.  These two plasmids were co-transformed into Jude-1 cells, and double 
selection was performed.  After stable lines were confirmed by sequencing, all lines were 
subcultured at an OD 600 of 0.05 and grown at the specified temperature while OD 600, 
GFP, and CFP fluorescence were monitored.  Data shown below are the ratios of 
180 190 200 
SD 
WT    .(((((..(((((((....))))))).))))).. 




Mut3-deletion  AUAUAC..GUUUUAGAUUUUUAGGAC.GUAUAAC 
Mut5-destabilized AUAUACAAGUUUUUUAUUUUUAGGACAGUAUAAC 
Mut6-no effect AAUAUCAAGUUUUAGAUUUUUAGGACAGAUAUAC 
Mut7-destabilized AAAAACAAGUUUUAGAUUUUUAGGACAGAAAAAC 
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GFP/CFP for Induced/Non-induced cells.  Cells were plated out in triplicate, and the 
statistics from those replicates are shown in the error bars below (Figure 5.5).   
Consistent with our hypothesis, variants possessing stabilizing mutations did not 
exhibit GFP/CFP fluorescence ratio changes across the temperatures assayed.  One 
destabilizing mutation, G178C, exhibited increased protein expression across all 
temperatures relative to the wild-type 5’ UTR.  All other destabilizing mutations 
exhibited similar fluorescence as wild-type at higher temperatures, while fluorescence at 
lower temperatures appeared to be higher than those observed for the wild-type 5’ UTR. 
 
Figure 5.5.  GFP/CFP ratios for LcrF 5’ UTR mutants at specified temperatures. 
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5.3.3 Real-Time PCR Assays 
RNA levels were examined using RNeasy (Qiagen) to isolate RNA, reverse 
transcription, and real-time PCR for GFP, CFP, and 16S rRNA.  16S rRNA C(T) ratios 
for 25°C and 37°C were used to normalize GFP and CFP measurements.  Results are 
shown below in Table 5.1. 
25°C 37°C
WT CFP 19.79 ± 0.15 19.92 ± 0.27
GFP 20.47 ± 0.05 20.13 ± 0.50
Mut 2 CFP 19.88 ± 0.71 20.54 ± 0.76
GFP 21.54 ± 0.50 22.09 ± 0.73
G178C CFP 20.26 ± 0.23 21.05 ± 0.34
GFP 20.60 ± 0.19 20.58 ± 0.29
C(T) Values
 
Table 5.1.  Real-Time PCR analysis of RNA levels for LcrF variants. 
 
For each variant of the LcrF 5’ UTR, C(T) values at 25°C and 37°C differed by 
less than one cycle, implying that RNA levels differ by less than 2-fold across 
temperatures.  In light of the invariance of RNA levels, the large change in protein 




Structural analysis reveals a stem-loop structure that was expected around the 
Shine-Dalgarno sequence, and protein fluorescence assays show that mutations to the 
stem-loop structure yield the expected results.  In addition, it appears that the internal 
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bubble directly following the Shine-Dalgarno sequence is extremely important for the 
function of the thermosensor, as deletion of the bubble or mutation to eliminate the 
bubble very effectively quench protein expression at higher temperatures.  In conjunction 
with the lack of change of the RNA levels at 25°C and 37°C, these results imply that the 
5’ UTR of LcrF acts as an RNA thermosensor to post-transcriptionally regulate protein 
levels with varying temperatures. 
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